STOCK TITAN

HeartCore raises going-concern warning in Q3 2026

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

HeartCore Enterprises, Inc. (HTCR) reported continuing-operations revenue of $269,852 for the nine months ended September 30, 2026, compared with $1,666,519 a year earlier, and a continuing-operations net loss of $3,148,329, versus $2,435,642. Third-quarter revenue was $162,409 versus $1,242,985; the quarter had a continuing-operations net loss of $568,666 compared with net income of $101,833.

HeartCore completed sales of 51% of Sigmaways on June 22, 2026, and 51% of HeartCore Luvina on August 17, 2026; its sale of 100% of HeartCore Japan closed October 31, 2025. The businesses are presented as discontinued operations, while continuing revenue comes from consulting services. Continuing operations used $3,348,933 of operating cash during the nine months, and cash and cash equivalents were $976,594 as of September 30, 2026.

The company said these conditions raise substantial doubt about its ability to continue as a going concern. It is exploring equity, debt or other financing and operational restructuring, but management could not conclude that the plans were probable of successful implementation. HeartCore also revised prior statements for income-tax calculation miscalculations it determined were not material to previously reported results or financial position.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointNine-month continuing net loss: $3,148,329 versus $2,435,642 in 2025.
  • Major pointGoing-concern disclosure: $3,348,933 nine-month operating cash use; $976,594 cash at September 30.
  • Moderate pointNine-month continuing revenue: $269,852 versus $1,666,519 in 2025.

Filing Explained

At September 30, 517 Series A preferred shares remained outstanding with an aggregate liquidation preference of $617,916.

The equity statement reports common shares outstanding of 1,270,991 on December 31, 2025 and 1,515,328 on September 30, 2026, with 1,553,308 outstanding on November 16, 2026, and it also records common-share issuance on preferred-share conversions and dividends, which increases the share count and reduces existing holders’ percentage ownership absent offsetting changes.

The equity statement records Series A conversions during the quarter, while 517 Series A convertible preferred shares remained outstanding at September 30, 2026.

Continuing-operations revenue $269,852 Nine months ended September 30, 2026; $1,666,519 in the comparable 2025 period
Continuing-operations revenue $162,409 Three months ended September 30, 2026; $1,242,985 in the comparable 2025 period
Net loss from continuing operations $3,148,329 loss Nine months ended September 30, 2026; $2,435,642 loss in 2025
Net loss attributable to common shareholders $3,737,907 loss Nine months ended September 30, 2026; $1,609,851 loss in 2025
Cash used in continuing operating activities $3,348,933 Nine months ended September 30, 2026; $2,342,190 in 2025
Cash and cash equivalents $976,594 As of September 30, 2026
Working capital $1.5 million As of September 30, 2026
discontinued operations financial
"presented as discontinued operations"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
substantial doubt financial
"raise substantial doubt about the Company’s ability to continue"
variable consideration financial
"constraint on variable consideration"
Amount of promised consideration in a contract whose final value depends on future events or uncertainties — for example discounts, rebates, performance bonuses, refunds, rights of return, or milestone payments. Under modern revenue-recognition rules (IFRS 15 / ASC 606) an entity estimates variable consideration using either the expected value or the most likely amount, then includes it in the transaction price only to the extent it is probable the estimate will not result in a significant reversal of cumulative revenue when the uncertainty is resolved. The estimate is updated as facts and circumstances change and the effect of any change is recognized in revenue.
embedded derivative financial
"definition of an embedded derivative"
An embedded derivative is a built-in feature inside a contract—like a bond, loan, or lease—that causes part of the payout to change based on something else, such as a stock price, interest rate, or commodity price. It matters to investors because that hidden feature can add separate risk and volatility to a security’s value and accounting treatment, like finding a removable engine in a car that changes how fast it can go and how much it’s worth.
Level 3 inputs financial
"used Level 3 inputs to determine fair value"
Level 3 inputs are the assumptions and estimates a company uses to value assets or liabilities when there is no observable market price, so the valuation relies heavily on internal models and judgment. For investors this matters because these valuations are less verifiable and more subject to error or bias—like estimating the value of a unique vintage car versus checking a price list—and can materially affect reported earnings and balance-sheet strength.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was HTCR's revenue for the first nine months of 2026?

HTCR reported $269,852 of continuing-operations revenue for the nine months ended September 30, 2026, compared with $1,666,519 in the year-earlier period. Third-quarter revenue was $162,409, versus $1,242,985.

Why did HTCR disclose substantial doubt about its ability to continue as a going concern?

HeartCore said the conditions raised substantial doubt, citing continuing-operations losses of $0.6 million for the quarter and $3.1 million for nine months, $3.3 million of nine-month operating cash use, and $1.0 million in cash. It also reported $1.5 million of working capital as of September 30, 2026. The company is exploring financing and restructuring options, but management could not conclude the plans were probable of successful implementation.

Which ownership stakes did HTCR sell?

HeartCore completed the sale of 51% of Sigmaways on June 22, 2026, and 51% of HeartCore Luvina on August 17, 2026. Its sale of 100% of HeartCore Japan closed October 31, 2025. The company presents these businesses as discontinued operations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001892322 0001892322 2026-01-01 2026-09-30 0001892322 2026-11-16 0001892322 2026-09-30 0001892322 2025-12-31 0001892322 us-gaap:NonrelatedPartyMember 2026-09-30 0001892322 us-gaap:NonrelatedPartyMember 2025-12-31 0001892322 us-gaap:RelatedPartyMember 2026-09-30 0001892322 us-gaap:RelatedPartyMember 2025-12-31 0001892322 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001892322 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001892322 2026-04-02 2026-04-02 0001892322 2026-07-01 2026-09-30 0001892322 2025-07-01 2025-09-30 0001892322 2025-01-01 2025-09-30 0001892322 us-gaap:PreferredStockMember 2024-12-31 0001892322 us-gaap:CommonStockMember 2024-12-31 0001892322 us-gaap:ReceivablesFromStockholderMember 2024-12-31 0001892322 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001892322 us-gaap:RetainedEarningsMember 2024-12-31 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001892322 us-gaap:ParentMember 2024-12-31 0001892322 us-gaap:NoncontrollingInterestMember 2024-12-31 0001892322 2024-12-31 0001892322 us-gaap:PreferredStockMember 2025-03-31 0001892322 us-gaap:CommonStockMember 2025-03-31 0001892322 us-gaap:ReceivablesFromStockholderMember 2025-03-31 0001892322 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001892322 us-gaap:RetainedEarningsMember 2025-03-31 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001892322 us-gaap:ParentMember 2025-03-31 0001892322 us-gaap:NoncontrollingInterestMember 2025-03-31 0001892322 2025-03-31 0001892322 us-gaap:PreferredStockMember 2025-06-30 0001892322 us-gaap:CommonStockMember 2025-06-30 0001892322 us-gaap:ReceivablesFromStockholderMember 2025-06-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001892322 us-gaap:RetainedEarningsMember 2025-06-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001892322 us-gaap:ParentMember 2025-06-30 0001892322 us-gaap:NoncontrollingInterestMember 2025-06-30 0001892322 2025-06-30 0001892322 us-gaap:PreferredStockMember 2025-12-31 0001892322 us-gaap:CommonStockMember 2025-12-31 0001892322 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001892322 us-gaap:RetainedEarningsMember 2025-12-31 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001892322 us-gaap:ParentMember 2025-12-31 0001892322 us-gaap:NoncontrollingInterestMember 2025-12-31 0001892322 us-gaap:PreferredStockMember 2026-03-31 0001892322 us-gaap:CommonStockMember 2026-03-31 0001892322 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001892322 us-gaap:RetainedEarningsMember 2026-03-31 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001892322 us-gaap:ParentMember 2026-03-31 0001892322 us-gaap:NoncontrollingInterestMember 2026-03-31 0001892322 2026-03-31 0001892322 us-gaap:PreferredStockMember 2026-06-30 0001892322 us-gaap:CommonStockMember 2026-06-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001892322 us-gaap:RetainedEarningsMember 2026-06-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001892322 us-gaap:ParentMember 2026-06-30 0001892322 us-gaap:NoncontrollingInterestMember 2026-06-30 0001892322 2026-06-30 0001892322 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001892322 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001892322 us-gaap:ReceivablesFromStockholderMember 2025-01-01 2025-03-31 0001892322 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001892322 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001892322 us-gaap:ParentMember 2025-01-01 2025-03-31 0001892322 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001892322 2025-01-01 2025-03-31 0001892322 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001892322 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001892322 us-gaap:ReceivablesFromStockholderMember 2025-04-01 2025-06-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001892322 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001892322 us-gaap:ParentMember 2025-04-01 2025-06-30 0001892322 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001892322 2025-04-01 2025-06-30 0001892322 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001892322 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001892322 us-gaap:ReceivablesFromStockholderMember 2025-07-01 2025-09-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001892322 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001892322 us-gaap:ParentMember 2025-07-01 2025-09-30 0001892322 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001892322 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001892322 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001892322 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001892322 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001892322 us-gaap:ParentMember 2026-01-01 2026-03-31 0001892322 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001892322 2026-01-01 2026-03-31 0001892322 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001892322 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001892322 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001892322 us-gaap:ParentMember 2026-04-01 2026-06-30 0001892322 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0001892322 2026-04-01 2026-06-30 0001892322 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001892322 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001892322 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0001892322 us-gaap:ParentMember 2026-07-01 2026-09-30 0001892322 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0001892322 us-gaap:PreferredStockMember 2025-09-30 0001892322 us-gaap:CommonStockMember 2025-09-30 0001892322 us-gaap:ReceivablesFromStockholderMember 2025-09-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001892322 us-gaap:RetainedEarningsMember 2025-09-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001892322 us-gaap:ParentMember 2025-09-30 0001892322 us-gaap:NoncontrollingInterestMember 2025-09-30 0001892322 2025-09-30 0001892322 us-gaap:PreferredStockMember 2026-09-30 0001892322 us-gaap:CommonStockMember 2026-09-30 0001892322 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001892322 us-gaap:RetainedEarningsMember 2026-09-30 0001892322 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0001892322 us-gaap:ParentMember 2026-09-30 0001892322 us-gaap:NoncontrollingInterestMember 2026-09-30 0001892322 HTCR:ShareExchangeAgreementMember HTCR:HeartCoreJapanMember 2021-07-16 2021-07-16 0001892322 HTCR:ShareExchangeAgreementMember HTCR:HeartCoreJapanMember 2021-07-16 0001892322 HTCR:ShareExchangeAgreementMember HTCR:HeartCoreJapanMember 2022-02-24 0001892322 2022-09-06 0001892322 HTCR:HeartCoreLuvinaMember 2023-11-30 0001892322 HTCR:HeartCoreJapanMember 2024-07-24 0001892322 HTCR:SigmawaysIncMember 2026-03-05 0001892322 HTCR:HeartCoreLuvinaMember 2026-07-31 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerAMember 2026-07-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerAMember 2025-07-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerAMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerAMember 2025-01-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerBMember 2026-07-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerBMember 2025-07-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerBMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerBMember 2025-01-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerCMember 2026-07-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerCMember 2025-07-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerCMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerCMember 2025-01-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerDMember 2026-07-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerDMember 2025-07-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerDMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerDMember 2025-01-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerEMember 2026-07-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerEMember 2025-07-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerEMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerEMember 2025-01-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerFMember 2026-07-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerFMember 2025-07-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerFMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerFMember 2025-01-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerGMember 2026-07-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerGMember 2025-07-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerGMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember HTCR:CustomerGMember 2025-01-01 2025-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember HTCR:CustomerAMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember HTCR:CustomerAMember 2025-01-01 2025-12-31 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember HTCR:CustomerHMember 2026-01-01 2026-09-30 0001892322 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember HTCR:CustomerHMember 2025-01-01 2025-12-31 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorAMember 2026-07-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorAMember 2025-07-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorAMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorAMember 2025-01-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorBMember 2026-07-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorBMember 2025-07-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorBMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorBMember 2025-01-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorCMember 2026-07-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorCMember 2025-07-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorCMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorCMember 2025-01-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorDMember 2026-07-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorDMember 2025-07-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorDMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember HTCR:VendorDMember 2025-01-01 2025-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorDMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorDMember 2025-01-01 2025-12-31 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorEMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorEMember 2025-01-01 2025-12-31 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorFMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorFMember 2025-01-01 2025-12-31 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorGMember 2026-01-01 2026-09-30 0001892322 us-gaap:SupplierConcentrationRiskMember HTCR:AccountsPayablesAndAccruedLiabilitiesMember HTCR:VendorGMember 2025-01-01 2025-12-31 0001892322 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001892322 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001892322 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001892322 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001892322 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001892322 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001892322 2025-01-01 0001892322 srt:ScenarioPreviouslyReportedMember 2025-12-31 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-12-31 0001892322 srt:RestatementAdjustmentMember 2025-12-31 0001892322 srt:ScenarioPreviouslyReportedMember 2025-01-01 2025-12-31 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-01-01 2025-12-31 0001892322 srt:RestatementAdjustmentMember 2025-01-01 2025-12-31 0001892322 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0001892322 us-gaap:ParentMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0001892322 srt:ScenarioPreviouslyReportedMember 2024-12-31 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2024-12-31 0001892322 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2024-12-31 0001892322 us-gaap:ParentMember srt:RestatementAdjustmentMember 2024-12-31 0001892322 srt:RestatementAdjustmentMember 2024-12-31 0001892322 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2025-01-01 2025-12-31 0001892322 us-gaap:ParentMember srt:ScenarioPreviouslyReportedMember 2025-01-01 2025-12-31 0001892322 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2025-01-01 2025-12-31 0001892322 us-gaap:ParentMember srt:RestatementAdjustmentMember 2025-01-01 2025-12-31 0001892322 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2025-12-31 0001892322 us-gaap:ParentMember srt:ScenarioPreviouslyReportedMember 2025-12-31 0001892322 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2025-12-31 0001892322 us-gaap:ParentMember srt:RestatementAdjustmentMember 2025-12-31 0001892322 srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-03-31 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-03-31 0001892322 srt:RestatementAdjustmentMember 2026-01-01 2026-03-31 0001892322 srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-04-01 2026-06-30 0001892322 srt:RestatementAdjustmentMember 2026-04-01 2026-06-30 0001892322 srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-01-01 2026-06-30 0001892322 srt:RestatementAdjustmentMember 2026-01-01 2026-06-30 0001892322 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-03-31 0001892322 us-gaap:ParentMember srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-03-31 0001892322 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2026-01-01 2026-03-31 0001892322 us-gaap:ParentMember srt:RestatementAdjustmentMember 2026-01-01 2026-03-31 0001892322 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2026-03-31 0001892322 us-gaap:ParentMember srt:ScenarioPreviouslyReportedMember 2026-03-31 0001892322 srt:ScenarioPreviouslyReportedMember 2026-03-31 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-03-31 0001892322 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2026-03-31 0001892322 us-gaap:ParentMember srt:RestatementAdjustmentMember 2026-03-31 0001892322 srt:RestatementAdjustmentMember 2026-03-31 0001892322 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001892322 us-gaap:ParentMember srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001892322 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2026-04-01 2026-06-30 0001892322 us-gaap:ParentMember srt:RestatementAdjustmentMember 2026-04-01 2026-06-30 0001892322 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2026-06-30 0001892322 us-gaap:ParentMember srt:ScenarioPreviouslyReportedMember 2026-06-30 0001892322 srt:ScenarioPreviouslyReportedMember 2026-06-30 0001892322 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-06-30 0001892322 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2026-06-30 0001892322 us-gaap:ParentMember srt:RestatementAdjustmentMember 2026-06-30 0001892322 srt:RestatementAdjustmentMember 2026-06-30 0001892322 HTCR:SumitakaYamamotoMember 2026-09-30 0001892322 HTCR:SumitakaYamamotoMember 2025-12-31 0001892322 2026-08-03 2026-08-03 0001892322 us-gaap:MachineryAndEquipmentMember 2026-09-30 0001892322 us-gaap:MachineryAndEquipmentMember 2025-12-31 0001892322 us-gaap:VehiclesMember 2026-09-30 0001892322 us-gaap:VehiclesMember 2025-12-31 0001892322 HTCR:InsurancePremiumFinancingAgreementMember HTCR:BankDirectCapitalFinanceMember 2024-01-31 0001892322 2024-06-28 0001892322 country:US 2026-01-01 2026-09-30 0001892322 country:JP 2026-01-01 2026-09-30 0001892322 HTCR:TwoThousandTwentyOneEquityIncentivePlanMember 2021-08-06 0001892322 HTCR:TwoThousandTwentyThreeEquityIncentivePlanMember 2023-08-01 0001892322 HTCR:OfficersDirectorsEmployeesAndConsultantsMember 2021-12-25 2021-12-25 0001892322 HTCR:OfficersDirectorsEmployeesAndConsultantsMember 2021-12-25 0001892322 HTCR:ThreePriorEmployeeMember 2022-08-09 2022-08-09 0001892322 HTCR:ThreePriorEmployeeMember 2022-08-09 0001892322 HTCR:EmployeeMember 2023-02-03 2023-02-03 0001892322 HTCR:EmployeeMember 2023-02-03 0001892322 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0001892322 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001892322 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001892322 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001892322 us-gaap:EmployeeStockOptionMember 2026-09-30 0001892322 HTCR:ExecutiveEmploymentAgreementMember HTCR:TwoThousandTwentyOneEquityIncentivePlanMember HTCR:FiveExecutivesMember 2022-02-09 2022-02-09 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2026-07-01 2026-09-30 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001892322 2024-01-01 2024-12-31 0001892322 2025-01-01 2025-12-31 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2025-09-30 0001892322 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001892322 HTCR:ATMAgreementMember 2023-10-23 0001892322 HTCR:ATMAgreementMember 2023-10-23 2023-10-23 0001892322 HTCR:ATMAgreementMember 2026-01-01 2026-09-30 0001892322 HTCR:ATMAgreementMember 2025-01-01 2025-09-30 0001892322 HTCR:ATMAgreementMember 2024-12-31 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember 2025-06-30 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember 2025-10-22 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember 2025-06-30 2025-06-30 0001892322 us-gaap:CommonStockMember 2025-06-30 2025-06-30 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember HTCR:SecuritiesPurchaseAgreementMember 2025-06-30 2025-06-30 0001892322 us-gaap:CommonStockMember HTCR:SecuritiesPurchaseAgreementMember 2025-06-30 2025-06-30 0001892322 HTCR:SecuritiesPurchaseAgreementMember 2025-06-30 2025-06-30 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember 2026-07-01 2026-09-30 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember 2026-01-01 2026-09-30 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember 2025-07-01 2025-09-30 0001892322 HTCR:SeriesAConvertiblePreferredSharesMember 2025-01-01 2025-09-30 0001892322 us-gaap:CommonStockMember HTCR:EquityPurchaseAgreementMember 2025-06-30 2025-06-30 0001892322 HTCR:EquityPurchaseAgreementMember 2025-06-30 2025-06-30 0001892322 HTCR:EquityPurchaseAgreementMember 2025-06-30 0001892322 us-gaap:CommonStockMember 2026-02-18 2026-02-18 0001892322 HTCR:TwoThousandTwentySixShareRepurchaseProgramMember 2026-03-04 2026-03-04 0001892322 us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001892322 us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001892322 us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001892322 us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001892322 us-gaap:SeriesAPreferredStockMember 2026-07-01 2026-09-30 0001892322 us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0001892322 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0001892322 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-09-30 0001892322 2025-07-24 2025-07-24 0001892322 2025-10-31 2025-10-31 0001892322 2026-03-05 2026-03-05 0001892322 HTCR:SemaphoreTechnologiesIncMember 2026-06-22 2026-06-22 0001892322 HTCR:SemaphoreTechnologiesIncMember 2026-01-01 2026-09-30 0001892322 HTCR:HeartCoreLuvinaMember 2026-07-31 2026-07-31 0001892322 HTCR:LuvinaSoftwareJointStockCompanyMember 2026-08-03 2026-08-03 0001892322 HTCR:LuvinaSoftwareJointStockCompanyMember 2026-01-01 2026-09-30 0001892322 HTCR:HeartCoreCoLtdMember 2026-01-01 2026-09-30 0001892322 HTCR:SigmawaysIncMember 2026-01-01 2026-09-30 0001892322 HTCR:HeartCoreLuvinaMember 2026-01-01 2026-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreCoLtdMember 2025-07-01 2025-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreCoLtdMember 2025-01-01 2025-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:SigmawaysIncMember 2026-07-01 2026-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:SigmawaysIncMember 2025-07-01 2025-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:SigmawaysIncMember 2026-01-01 2026-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:SigmawaysIncMember 2025-01-01 2025-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreLuvinaMember 2026-07-01 2026-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreLuvinaMember 2025-07-01 2025-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreLuvinaMember 2026-01-01 2026-09-30 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreLuvinaMember 2025-01-01 2025-09-30 0001892322 HTCR:SigmawaysMember 2026-06-22 2026-06-22 0001892322 HTCR:HeartCoreLuvinaMember 2026-08-17 2026-08-17 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:SigmawaysIncMember 2025-06-22 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:SigmawaysIncMember 2025-12-31 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreLuvinaMember 2026-08-17 0001892322 us-gaap:SegmentDiscontinuedOperationsMember HTCR:HeartCoreLuvinaMember 2025-12-31 0001892322 us-gaap:SegmentDiscontinuedOperationsMember us-gaap:NonrelatedPartyMember 2026-08-17 0001892322 us-gaap:SegmentDiscontinuedOperationsMember us-gaap:NonrelatedPartyMember 2025-12-31 0001892322 us-gaap:SegmentDiscontinuedOperationsMember us-gaap:RelatedPartyMember 2026-08-17 0001892322 us-gaap:SegmentDiscontinuedOperationsMember us-gaap:RelatedPartyMember 2025-12-31 0001892322 HTCR:SigmawaysAndItsWhollyOwnedSubsidiariesMember 2026-09-30 0001892322 HTCR:SigmawaysAndItsWhollyOwnedSubsidiariesMember 2025-12-31 0001892322 HTCR:HeartCoreLuvinaMember 2026-09-30 0001892322 HTCR:HeartCoreLuvinaMember 2025-12-31 0001892322 HTCR:SingleReportableSegmentMember 2026-01-01 2026-09-30 0001892322 us-gaap:SubsequentEventMember HTCR:TwoThousandTwentyThreeEquityIncentivePlanMember HTCR:ThreeExecutiveOfficerMember 2026-10-06 2026-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure HTCR:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______, 20___, to _____, 20___.

 

Commission File Number 001-41272

 

HeartCore Enterprises, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   87-0913420
(State or Other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer
Identification Number)

 

14F, Shibuya Sakura Stage Central Building,

1-2 Sakuragaoka-cho,

Shibuya-ku, Tokyo, Japan 150-0031

(Address of Principal Executive Offices) (Zip Code)

 

+81-3-6899-7114

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each Exchange on which Registered
Common Stock   HTCR   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☒    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 16, 2026, there were 1,553,308 shares of outstanding common stock of the registrant.

 

 

 

 

 

 

HeartCore Enterprises, Inc.

 

Contents

 

  Page
PART I - FINANCIAL INFORMATION  
     
Item 1. Financial Statements F-1
     
  Unaudited Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 F-1
     
  Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2026 and 2025 F-2
     
  Unaudited Consolidated Statements of Changes in Shareholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 F-3
     
  Unaudited Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 F-4
     
  Notes to Unaudited Consolidated Financial Statements F-5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 1
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 11
     
Item 4. Controls and Procedures 11
     
PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 12
     
Item 1A. Risk Factors 12
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 12
     
Item 3. Defaults Upon Senior Securities 12
     
Item 4. Mine Safety Disclosures 12
     
Item 5. Other Information 12
     
Item 6. Exhibits 12
     
Signatures 13

 

i

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS 

 

HEARTCORE ENTERPRISES, INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

 

   September 30,   December 31, 
   2026   2025 
ASSETS          
Current assets:          
Cash and cash equivalents  $976,594   $1,530,967 
Accounts receivable   32,853    - 
Investments in marketable securities   1,380,553    3,690,187 
Prepaid expenses   82,351    127,242 
Deferred offering costs   250,000    250,000 
Other current assets   144,079    188,525 
Current assets of discontinued operations   -    1,337,673 
Proceeds receivable from sale of discontinued operations   483,082    1,291,298 
Total current assets   3,349,512    8,415,892 
           
Non-current assets:          
Property and equipment, net   255,872    275,465 
Operating lease right-of-use assets   352,524    16,986 
Long-term investment in warrants   130,916    280,924 
Long-term loan receivable   258,859    - 
Deferred tax assets   23,006    23,121 
Security deposits   276,199    278,342 
Other non-current assets   286    - 
Non-current assets of discontinued operations   -    33,752 
Long-term proceeds receivable from sale of discontinued operations   3,496,039    3,736,995 
Total non-current assets   4,793,701    4,645,585 
           
Total assets  $8,143,213   $13,061,477 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable and accrued expenses  $454,345   $275,412 
Accrued payroll and other employee costs   41,859    41,073 
Due to related party   423    285 
Insurance premium financing   33,736    13,430 
Operating lease liabilities, current   284,622    16,986 
Income tax payables   20,564    1,038 
Deferred revenue   438,862    676,216 
Derivative liability   62,507    121,719 
Other current liabilities   530,070    521,607 
Current liabilities of discontinued operations   -    1,833,294 
Total current liabilities   1,866,988    3,501,060 
           
Non-current liabilities:          
Operating lease liabilities, non-current   71,912    - 
Deferred tax liabilities   211,795    1,039,181 
Non-current liabilities of discontinued operations   -    448,376 
Total non-current liabilities   283,707    1,487,557 
           
Total liabilities   2,150,695    4,988,617 
           
Shareholders’ equity:          
Preferred shares, $0.0001 par value, 20,000,000 shares authorized; Series A convertible preferred shares, 4,000 shares designated, 517 and 1,017 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; aggregate liquidation preference of $617,916 and $1,158,362 as of September 30, 2026 and December 31, 2025, respectively   351,712    691,858 
Common shares, $0.0001 par value, 200,000,000 shares authorized, 1,515,328 and 1,270,991 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively*   151    127 
Additional paid-in capital   22,309,504    21,902,169 
Accumulated deficit   (16,640,902)   (12,965,525)
Accumulated other comprehensive loss   (27,947)   (58,497)
Total HeartCore Enterprises, Inc. shareholders’ equity   5,992,518    9,570,132 
Non-controlling interests   -    (1,497,272)
Total shareholders’ equity   5,992,518    8,072,860 
           
Total liabilities and shareholders’ equity  $8,143,213   $13,061,477 

 

* On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company’s issued and outstanding common shares. References to share and per share information of common shares in the unaudited consolidated financial statements have been retroactively adjusted. See NOTE 12.

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

F-1
 

 

HEARTCORE ENTERPRISES, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

 

   2026   2025   2026   2025 
   For the Three Months   For the Nine Months 
   Ended September 30,   Ended September 30, 
   2026   2025   2026   2025 
Revenues  $162,409   $1,242,985   $269,852   $1,666,519 
Cost of revenues   146,354    141,460    529,562    331,962 
Gross profit (loss)   16,055    1,101,525    (259,710)   1,334,557 
                     
Operating expenses:                    
Selling expenses   34,818    82,036    104,021    296,632 
General and administrative expenses   1,119,034    817,160    2,986,544    2,488,822 
Total operating expenses   1,153,852    899,196    3,090,565    2,785,454 
                     
Income (loss) from continuing operations   (1,137,797)   202,329    (3,350,275)   (1,450,897)
                     
Other income (expenses):                    
Changes in fair value of investments in marketable securities   442,124    20,539    (375,367)   (908,416)
Changes in fair value of investment in warrants   9,142    (146,769)   (7,493)   (74,109)
Changes in fair value of derivative liability   (47,888)   (9,679)   (630)   (9,679)
Interest income   749    843    1,100    3,966 
Interest expenses   (1,909)   (2,695)   (6,386)   (8,569)
Other income   159,034    39,308    186,056    45,632 
Other expenses   (16,398)   (4)   (361,838)   (193)
Total other income (expenses)   544,854    (98,457)   (564,558)   (951,368)
                     
Income (loss) from continuing operations before income tax expense (benefit)   (592,943)   103,872    (3,914,833)   (2,402,265)
Income tax expense (benefit)   (24,277)   2,039    (766,504)   33,377 
Net income (loss) from continuing operations   (568,666)   101,833    (3,148,329)   (2,435,642)
Income (loss) from discontinued operations, net of income tax   (27,768)   249,342    (644,329)   710,942 
Net income (loss)   (596,434)   351,175    (3,792,658)   (1,724,700)
Less: income (loss) from discontinued operations attributable to non-controlling interests   4,166    (82,897)   (117,281)   (171,682)
Net income (loss) attributable to HeartCore Enterprises, Inc.   (600,600)   434,072    (3,675,377)   (1,553,018)
Dividends accrued on Series A convertible preferred shares   (15,206)   (56,222)   (62,530)   (56,833)
Net income (loss) attributable to HeartCore Enterprises, Inc. common shareholders  $(615,806)  $377,850   $(3,737,907)  $(1,609,851)
                     
Other comprehensive income (loss):                    
Foreign currency translation adjustment   (38,193)   (38,370)   (72,706)   9,668 
Cumulative translation adjustment reclassified into earnings due to disposal of discontinued operations   13,380    -    94,751    - 
Total comprehensive income (loss)   (621,247)   312,805    (3,770,613)   (1,715,032)
Less: comprehensive income (loss) attributable to non-controlling interests   4,598    (85,418)   (125,786)   (175,353)
Comprehensive income (loss) attributable to HeartCore Enterprises, Inc.  $(625,845)  $398,223   $(3,644,827)  $(1,539,679)
                     
Net income (loss) from continuing operations attributable to HeartCore Enterprises, Inc. per common share*                    
Basic  $(0.39)  $0.04   $(2.30)  $(2.22)
Diluted  $(0.39)  $0.04   $(2.30)  $(2.22)
                     
Income (loss) from discontinued operations per common share*                    
Basic  $(0.02)  $0.29   $(0.38)  $0.78 
Diluted  $(0.02)  $0.29   $(0.38)  $0.78 
                     
Net income (loss) attributable to HeartCore Enterprises, Inc. per common share*                    
Basic  $(0.41)  $0.32   $(2.68)  $(1.43)
Diluted  $(0.41)  $0.32   $(2.68)  $(1.43)
                     
Weighted average common shares outstanding*                    
Basic   1,501,177    1,165,539    1,395,177    1,124,484 
Diluted   1,501,177    1,165,539    1,395,177    1,124,484 

 

* On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company’s issued and outstanding common shares. References to share and per share information of common shares in the unaudited consolidated financial statements have been retroactively adjusted. See NOTE 12.

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

F-2
 

 

HEARTCORE ENTERPRISES, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

 

   Shares   Amount   Shares*   Amount   Receivable   Capital   Deficit   Income   Equity   Interests   Equity 
                       Accumulated   Total HeartCore         
   Preferred Shares   Common Shares       Additional       Other   Enterprises, Inc.   Non-   Total 
   Number of       Number of       Subscription   Paid-in   Accumulated   Comprehensive   Shareholders’   controlling   Shareholders’ 
   Shares   Amount   Shares*   Amount   Receivable   Capital   Deficit   Income   Equity   Interests   Equity 
Balance, January 1, 2025                    -   $-       1,096,900   $110   $(103,942)  $20,658,236   $(15,557,374)  $343,936   $5,340,966   $(1,191,482)  $4,149,484 
Net loss   -    -    -    -    -    -    (3,086,992)   -    (3,086,992)   (50,389)   (3,137,381)
Foreign currency translation adjustment   -    -    -    -    -    -    -    (9,251)   (9,251)   1,237    (8,014)
Issuance of common shares related to at the market offering agreement   -    -    794    -    -    30,445    -    -    30,445    -    30,445 
Collection of subscription receivable   -    -    -    -    103,942    -    -    -    103,942    -    103,942 
Exercise of stock options   -    -    5,000    1    -    116,999    -    -    117,000    -    117,000 
Stock-based compensation   -    -    1,073    -    -    32,280    -    -    32,280    -    32,280 
Balance, March 31, 2025   -    -    1,103,767    111    -    20,837,960    (18,644,366)   334,685    2,528,390    (1,240,634)   1,287,756 
Net income (loss)   -    -    -    -    -    -    1,099,902    -    1,099,902    (38,396)   1,061,506 
Foreign currency translation adjustment   -    -    -    -    -    -    -    58,439    58,439    (2,387)   56,052 
Issuance of Series A convertible preferred shares   2,000    1,360,586    -    -    -    -    -    -    1,360,586    -    1,360,586 
Issuance of common shares related to securities purchase agreement   -    -    37,500    4    -    203,269    -    -    203,273    -    203,273 
Issuance of common shares related to equity purchase agreement   -    -    24,272    2    -    249,998    -    -    250,000    -    250,000 
Dividends accrued on Series A convertible preferred shares   -    -    -    -    -    (611)   -    -    (611)   -    (611)
Stock-based compensation   -    -    -    -    -    27,924    -    -    27,924    -    27,924 
Balance, June 30, 2025   2,000    1,360,586    1,165,539    117    -    21,318,540    (17,544,464)   393,124    5,527,903    (1,281,417)   4,246,486 
Net income (loss)   -    -    -    -    -    -    434,072    -    434,072    (82,897)   351,175 
Foreign currency translation adjustment   -    -    -    -    -    -    -    (35,849)   (35,849)   (2,521)   (38,370)
Dividends accrued on Series A convertible preferred shares   -    -    -    -    -    (56,222)   -    -    (56,222)   -    (56,222)
Stock-based compensation   -    -    -    -    -    9,018    -    -    9,018    -    9,018 
Balance, September 30, 2025   2,000   $1,360,586    1,165,539   $117   $-   $21,271,336   $(17,110,392)  $357,275   $5,878,922   $(1,366,835)  $4,512,087 

 

   Shares   Amount   Shares*   Amount   Capital   Deficit   Loss   Equity   Interests   Equity 
                       Accumulated   Total HeartCore         
   Preferred Shares   Common Shares   Additional       Other   Enterprises, Inc.   Non-   Total 
   Number of       Number of       Paid-in   Accumulated   Comprehensive   Shareholders’   controlling   Shareholders’ 
   Shares   Amount   Shares*   Amount   Capital   Deficit   Loss   Equity   Interests   Equity 
Balance, January 1, 2026             1,017   $691,858       1,270,991   $127   $21,902,169   $(12,965,525)  $(58,497)  $      9,570,132   $(1,497,272)  $8,072,860 
Net loss   -    -    -    -    -    (1,462,650)   -    (1,462,650)   (105,008)   (1,567,658)
Foreign currency translation adjustment   -    -    -    -    -    -    (7,602)   (7,602)   (8,538)   (16,140)
Dividends accrued on Series A convertible preferred shares   -    -    -    -    (27,968)   -    -    (27,968)   -    (27,968)
Stock-based compensation   -    -    796    -    2,031    -    -    2,031    -    2,031 
Balance, March 31, 2026   1,017    691,858    1,271,787    127    21,876,232    (14,428,175)   (66,099)   8,073,943    (1,610,818)   6,463,125 
Net loss   -    -    -    -    -    (1,612,127)   -    (1,612,127)   (16,439)   (1,628,566)
Foreign currency translation adjustment   -    -    -    -    -    -    (17,974)   (17,974)   (399)   (18,373)
Cumulative translation adjustment reclassified into earnings due to disposal of discontinued operations   -    -    -    -    -    -    81,371    81,371    -    81,371 
Derecognition of non-controlling interests upon sale of discontinued operations   -    -    -    -    -    -    -    -    1,798,448    1,798,448 
Series A convertible preferred shares converted to common shares   (400)   (272,117)   152,753    15    272,102    -    -    -    -    - 
Dividends accrued on Series A convertible preferred shares   -    -    -    -    (19,356)   -    -    (19,356)   -    (19,356)
Reverse stock split rounding adjustment   -    -    17,025    2    (2)   -    -    -    -    - 
Balance, June 30, 2026   617    419,741    1,441,565    144    22,128,976    (16,040,302)   (2,702)   6,505,857    170,792    6,676,649 
Net income (loss)   -    -    -    -    -    (600,600)   -    (600,600)   4,166    (596,434)
Foreign currency translation adjustment   -    -    -    -    -    -    (38,625)   (38,625)   432    (38,193)
Cumulative translation adjustment reclassified into earnings due to disposal of discontinued operations   -    -    -    -    -    -    13,380    13,380    -    13,380 
Derecognition of non-controlling interests upon sale of discontinued operations   -    -    -    -    -    -    -    -    (175,390)   (175,390)
Series A convertible preferred shares converted to common shares   (100)   (68,029)   49,077    5    127,866    -    -    59,842    -    59,842 
Issuance of common shares for dividends on Series A convertible preferred shares   -    -    24,686    2    67,868    -    -    67,870    -    67,870 
Dividends accrued on Series A convertible preferred shares   -    -    -    -    (15,206)   -    -    (15,206)   -    (15,206)
Balance, September 30, 2026   517   $351,712    1,515,328   $151   $22,309,504   $(16,640,902)  $(27,947)  $5,992,518   $-   $5,992,518 

 

* On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company’s issued and outstanding common shares. References to share and per share information of common shares in the unaudited consolidated financial statements have been retroactively adjusted. See NOTE 12.

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

F-3
 

 

HEARTCORE ENTERPRISES, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   2026   2025 
   For the Nine Months 
   Ended September 30, 
   2026   2025 
Cash flows from operating activities of continuing operations:          
Net loss  $(3,792,658)  $(1,724,700)
Income (loss) from discontinued operations, net of income tax   (644,329)   710,942 
Net loss from continuing operations   (3,148,329)   (2,435,642)
Adjustments to reconcile net loss from continuing operations to net cash flows used in operating activities of continuing operations:          
Depreciation expense   23,023    36,994 
Loss on disposal of property and equipment   -    116,981 
Non-cash lease expense   195,691    28,167 
Gain on termination of lease   -    (9,059)
Deferred income taxes   (796,046)   29,680 
Stock-based compensation   2,031    69,222 
Warrants received as noncash consideration   -    (837,913)
Changes in fair value of investments in marketable securities   375,367    908,416 
Changes in fair value of investment in warrants   7,493    74,109 
Changes in fair value of derivative liability   630    9,679 
Gain on settlement of asset retirement obligations   -    (45,873)
Changes in assets and liabilities:          
Accounts receivable   (32,826)   - 
Prepaid expenses   152,391    114,556 
Other assets   93,367    137,050 
Accounts payable and accrued expenses   178,373    (98,030)
Accrued payroll and other employee costs   988    (43,430)
Due to related party   138    - 
Operating lease liabilities   (191,710)   (21,135)
Income tax payables   19,382    (97,537)
Deferred revenue   (237,354)   (278,421)
Other liabilities   8,458    (4)
Net cash flows used in operating activities of continuing operations   (3,348,933)   (2,342,190)
           
Cash flows from investing activities of continuing operations:          
Purchases of property and equipment   (4,931)   - 
Proceeds from sale of marketable securities   2,076,782    1,071,732 
Advances on loan receivable   (256,932)   - 
Proceeds from sales of discontinued operations, net of cash divested   825,663    - 
Net cash flows provided by investing activities of continuing operations   2,640,582    1,071,732 
           
Cash flows from financing activities of continuing operations:          
Payments for finance lease   -    (12,692)
Repayment of insurance premium financing   (87,694)   (103,303)
Proceeds from issuance of common shares related to at the market offering agreement   -    30,445 
Proceeds from collection of subscription receivable   -    103,942 
Proceeds from exercise of stock options   -    117,000 
Proceeds from issuance of Series A convertible preferred shares and common shares related to securities purchase agreement, net of share issuance costs   -    1,800,000 
Net cash flows provided by (used in) financing activities of continuing operations   (87,694)   1,935,392 
           
Cash flows from discontinued operations:          
Net cash flows used in operating activities of discontinued operations   (119,498)   (511,096)
Net cash flows provided by (used in) investing activities of discontinued operations   (1,432)   29,222 
Net cash flows used in financing activities of discontinued operations   (22,134)   (305,990)
Net cash flows used in discontinued operations   (143,064)   (787,864)
           
Effect of exchange rate changes   (70,259)   26,577 
           
Net change in cash and cash equivalents   (1,009,368)   (96,353)
Cash and cash equivalents - beginning of the period   1,985,962    2,121,089 
Cash and cash equivalents - end of the period  $976,594   $2,024,736 
           
Supplemental cash flow disclosures:          
Interest paid  $32,583   $88,321 
Income taxes paid  $14,197   $131,118 
           
Non-cash investing and financing transactions:          
Insurance premium financing  $108,000   $139,500 
Warrants converted to marketable securities  $142,515   $388,260 
Operating lease right-of-use assets obtained in exchange for operating lease liabilities  $552,577   $23,495 
Issuance of common shares related to equity purchase agreement  $-   $250,000 
Dividends accrued on Series A convertible preferred shares  $62,530   $56,833 
Issuance of common shares for dividends on Series A convertible preferred shares  $67,870   $- 
Series A convertible preferred shares converted to common shares  $340,146   $- 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

F-4
 

 

HEARTCORE ENTERPRISES, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

HeartCore Enterprises, Inc. (“HeartCore USA”), a holding company, was incorporated under the laws of the State of Delaware on May 18, 2021.

 

On July 16, 2021, HeartCore USA executed a share exchange agreement with certain shareholders of HeartCore Co., Ltd. (“HeartCore Japan”), a company that was incorporated in Japan on June 12, 2009. Pursuant to the terms of the share exchange agreement, HeartCore USA issued 800,000 shares of its common shares to the shareholders of HeartCore Japan in exchange for 10,706 shares out of 10,984 shares of common shares issued by HeartCore Japan, representing approximately 97.5% of HeartCore Japan’s outstanding common shares. On February 24, 2022, HeartCore USA purchased the remaining 278 shares of common shares of HeartCore Japan. As a result, HeartCore Japan became a wholly-owned operating subsidiary of HeartCore USA.

 

The share exchange on July 16, 2021 has been accounted for as a recapitalization between entities under common control since the same controlling shareholders controlled these two entities before and after the transaction. The consolidation of HeartCore USA and its subsidiary has been accounted for at historical cost and prepared on the basis as if the transaction had become effective as of the beginning of the earliest period presented in the unaudited consolidated financial statements.

 

HeartCore USA, via its wholly-owned operating subsidiary, HeartCore Japan, which was disposed of on October 31, 2025, was mainly engaged in the business of developing and sales of comprehensive software prior to disposition of software business. Beginning from early 2022, HeartCore USA is engaged in the business of providing consulting services to Japanese companies with intention to go public in the United States capital market.

 

On September 6, 2022, HeartCore USA entered into a share exchange and purchase agreement to acquire 51% of the outstanding shares of Sigmaways, Inc. (“Sigmaways”), a company incorporated under the laws of the State of California in April 2006, and its wholly-owned subsidiaries, Sigmaways B.V. and Sigmaways Technologies Ltd. (“Sigmaways Technologies”). Sigmaways B.V. was incorporated in Netherlands in November 2019. Sigmaways Technologies was incorporated in Canada in August 2020. Sigmaways and its wholly-owned subsidiaries are primarily engaged in the business of providing software development and other services in the United States. The acquisition was closed on February 1, 2023.

 

In January 2023, HeartCore USA incorporated a wholly-owned subsidiary, HeartCore Financial, Inc. (“HeartCore Financial”), under the laws of the State of Delaware. HeartCore Financial is engaged in the business of providing consulting services.

 

In November 2023, HeartCore Japan established a 51% owned subsidiary in Vietnam, HeartCore Luvina Vietnam Company Limited (“HeartCore Luvina”), which is engaged in the business of providing software development and other services. HeartCore Luvina started its operations from February 2024. In October 2025, HeartCore Japan transferred 51% of the outstanding shares of HeartCore Luvina to HeartCore USA.

 

In April 2024, HeartCore Financial incorporated a branch office, HeartCore Financial, Inc. – Japan Branch Office (“HeartCore Financial – Japan”), in Japan. HeartCore Financial – Japan is engaged in the business of providing consulting services.

 

On July 24, 2025, the Board of Directors approved to enter into a non-binding letter of intent to sell 100% of the outstanding shares of HeartCore Japan. The sale of HeartCore Japan represented a strategic shift that had a major impact on the results of operations and has been accounted for as a discontinued operation (see NOTE 14). The sale transaction was closed on October 31, 2025.

 

F-5
 

 

In October 2025, HeartCore USA incorporated a wholly-owned subsidiary, Higgs Field Co., Ltd. (“Higgs Field”), in Japan. Higgs Field is engaged in the business of providing business and management consulting services.

 

On March 5, 2026, the Board of Directors approved to sell 51% of the outstanding shares of Sigmaways and its wholly-owned subsidiaries. The sale of Sigmaways and its wholly-owned subsidiaries represented a strategic shift that had a major impact on the results of operations and has been accounted for as a discontinued operation (see NOTE 14). The sale transaction was closed on June 22, 2026.

 

On July 31, 2026, the Board of Directors approved to sell 51% of the outstanding shares of HeartCore Luvina. The sale of HeartCore Luvina represented a strategic shift that had a major impact on the results of operations and has been accounted for as a discontinued operation (see NOTE 14). The sale transaction was closed on August 17, 2026.

 

HeartCore USA, HeartCore Japan, Sigmaways, Sigmaways B.V., Sigmaways Technologies, HeartCore Financial, HeartCore Luvina, HeartCore Financial – Japan and Higgs Field are hereafter referred to as the “Company” unless specific reference is made to an entity.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim consolidated financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The unaudited consolidated financial statements include the accounts of HeartCore USA and its subsidiaries. The Company has presented the assets and liabilities of HeartCore Japan, Sigmaways and its wholly-owned subsidiaries and HeartCore Luvina and their results of operations and cash flows as discontinued operations in the unaudited consolidated financial statements as of and for all periods presented. All footnotes exclude balances and activities of HeartCore Japan, Sigmaways and its wholly-owned subsidiaries and HeartCore Luvina unless otherwise noted. All significant intercompany accounts and transactions have been eliminated.

 

These unaudited interim consolidated financial statements do not include all of the information and disclosures required by the U.S. GAAP for complete consolidated financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments consisting of normal recurring nature considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been included. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2025.

 

Liquidity and Going Concern

 

The unaudited consolidated financial statements have been prepared in accordance with U.S. GAAP assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company assesses whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.

 

The Company incurred net loss from continuing operations of $0.6 million and $3.1 million for the three and nine months ended September 30, 2026, respectively, and net cash flows used in operating activities of continuing operations of $3.3 million for the nine months ended September 30, 2026, primarily due to the macroeconomic downturn environment. As of September 30, 2026, the Company had cash and cash equivalents of $1.0 million, working capital of $1.5 million and accumulated deficit of $16.6 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company’s plan is to continue exploring strategic alternatives for raising additional funding for future operations through a combination of obtaining equity financing, entering into debt or other financing arrangements, and restructuring of operations to grow revenues and decrease expenses to supplement the Company’s liquidity. The Company’s ability to raise capital may be constrained by the price of and demand for the Company’s equity shares. Additional funding may not be available on favorable terms or at all, and could further dilute the Company’s current shareholders. Management cannot conclude as of the date of this report that its plans are probable of being successfully implemented. There can be no assurance that the Company will be able to obtain sufficient additional liquidity when needed or under acceptable terms, if at all.

 

F-6
 

 

The unaudited consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company is unable to continue as a going concern.

 

Use of Estimates

 

In preparing the unaudited consolidated financial statements in conformity U.S. GAAP, the management is required to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information available as of the date of the unaudited consolidated financial statements. Estimates required to be made by management include, but are not limited to, allowance for credit losses, useful life of property and equipment, impairment of long-lived assets, valuation of stock-based compensation, valuation allowance of deferred tax assets, uncertain tax positions, implicit interest rate of operating and finance leases, valuation of investment in warrants, and valuation of derivative liability. Actual results could differ from those estimates.

 

Investment in Warrants

 

Investment in warrants represents stock warrants earned from its consulting service customers. The warrants are measured at fair value and any changes in fair value are recognized in other income (expenses). Investment in warrants is classified as long-term if the warrants are exercisable over one year after the date of receipt.

 

Investments in Marketable Securities

 

Investments in marketable securities represent equity securities registered for public sale with readily determinable fair value. The marketable securities are obtained through stocks of its customers received as noncash consideration from consulting services and through exercise of stock warrants of its consulting service customers and measured at fair value with any changes in fair value recognized in other income (expenses).

 

Impairment of Long-Lived Assets

 

Long-lived assets with finite lives, primarily property and equipment and operating lease right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated cash flows from the use of the asset and its eventual disposition are below the asset’s carrying value, then the asset is deemed to be impaired and written down to its fair value. There were no impairments of these assets during the three and nine months ended September 30, 2026 and 2025.

 

Foreign Currency Translation

 

The functional currency of HeartCore Japan, HeartCore Financial – Japan and Higgs Field is the Japanese Yen (“JPY”). The functional currency of HeartCore USA, HeartCore Financial and Sigmaways is the United States Dollar (“US$”). The functional currency of Sigmaways B.V. is the Euro (“EUR”). The functional currency of Sigmaways Technologies is the Canada Dollar (“CAD”). The functional currency of HeartCore Luvina is the Vietnam Dong (“VND”). Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the unaudited consolidated statements of operations and comprehensive income (loss).

 

The reporting currency of the Company is the US$, and the unaudited consolidated financial statements have been expressed in the US$. In accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 830-30, “Translation of Financial Statements”, assets and liabilities of the Company whose functional currency is not US$ are translated into US$, using the exchange rates on the balance sheet dates. Revenues and expenses are translated at average rates prevailing during the periods. The gains and losses resulting from the translation of financial statements are recorded as a separate component of accumulated other comprehensive income (loss) within the unaudited consolidated statements of changes in shareholders’ equity.

 

F-7
 

 

Revenue Recognition

 

The Company recognizes revenues under ASC Topic 606, “Revenue from Contracts with Customers”.

 

To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenues when (or as) the Company satisfies a performance obligation. Revenues amount represents the invoiced value, net of a value-added tax (“Consumption Tax”) and applicable local government levies. The Consumption Tax on sales are calculated at 10% of gross sales in Japan and nil of gross sales in the United States.

 

The Company currently generates its revenues from providing consulting services.

 

Revenues from Consulting Services

 

The Company provides public listing related consulting services to customers pursuant to the specific requirements prescribed in the contracts, which primarily include communicating with intermediary parties, preparing required documents related to the initial public offering and supporting the listing process. The consulting services contracts normally include both cash and noncash considerations. Cash consideration is paid in installment payments and is recognized in revenues over the period of the contract by reference to progress toward complete satisfaction of that performance obligation. Noncash consideration is in the form of stocks and warrants of the customers and is measured at fair value at contract inception. Noncash consideration that is variable for reasons other than only the form of the consideration is included in the transaction price, but is subject to the constraint on variable consideration. The Company assesses the estimated amount of the variable noncash consideration at contract inception and subsequently, to determine when and to what extent it is probable that a significant reversal of cumulative revenues recognized will not occur once the uncertainty associated with the variable consideration is subsequently resolved. Only when the significant revenues reversal is concluded probable of not occurring can variable consideration be included in revenues. Based on evaluation of likelihood and magnitude of a reversal in applying the constraint, the variable noncash consideration is recognized in revenues until the underlying uncertainties have been resolved.

 

Contract Balances

 

The timing of revenue recognition may differ from the timing of invoicing to the customers. The Company determines that its contracts do not include a significant financing component. The Company records a contract asset, which is included in accounts receivable in the consolidated balance sheets, when revenues are recognized prior to invoicing. The Company records deferred revenue in the consolidated balance sheets when revenues are recognized subsequent to cash collection for an invoice. Deferred revenue is reported net of related uncollected deferred revenue in the consolidated balance sheets. The amounts of revenues recognized during the nine months ended September 30, 2026 and 2025 that were included in the opening deferred revenue balances were approximately $0.2 million and $0.6 million, respectively.

 

F-8
 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts receivable, other receivable, loan receivable and proceeds receivable from sale of discontinued operations. The Company usually does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers and counter parties to minimize collection risk on receivables.

 

For the three and nine months ended September 30, 2026 and 2025, customers account for 10% or more of the Company’s revenues are as follows:

 

  

For the Three Months

Ended September 30,

  

For the Nine Months

Ended September 30,

 
   2026   2025   2026   2025 
Customer A   37.2%   -*    14.3%   12.6%
Customer B   21.1%   *    -*    -* 
Customer C   14.6%   *    46.7%   * 
Customer D   13.2%   -*    -*    -* 
Customer E   11.9%   -*    29.9%   11.7%
Customer F   -*    64.8%   -*    51.1%
Customer G   -*    10.8%   *    -* 

 

As of September 30, 2026 and December 31, 2025, customers account for 10% or more of the Company’s accounts receivable are as follows:

 

   September 30,   December 31, 
   2026   2025 
Customer A   88.9%   -* 
Customer H   11.1%   -* 

 

For the three and nine months ended September 30, 2026 and 2025, vendors account for 10% or more of the Company’s purchases from continuing operations are as follows:

 

  

For the Three Months

Ended September 30,

  

For the Nine Months

Ended September 30,

 
   2026   2025   2026   2025 
Vendor A   13.3%   *    -*    -* 
Vendor B   10.4%   21.3%   10.7%   14.1%
Vendor C   -*    12.8%   15.8%   27.9%
Vendor D   -*    14.5%   11.6%   -* 

 

As of September 30, 2026 and December 31, 2025, vendors account for 10% or more of the Company’s accounts payable and accrued expenses are as follows:

 

   September 30,   December 31, 
   2026   2025 
Vendor D   -*    12.7%
Vendor E   35.4%   58.4%
Vendor F   12.9%   -* 
Vendor G   11.9%   -* 

 

* Less than 10%.

 

F-9
 

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting”, requires use of the management approach model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker (“CODM”) organizes segments within the Company for making operating decisions, assessing performance and allocating resources. Reportable segments are based on services, geography, legal structure, management structure, or any other manner in which management disaggregates a company (see NOTE 15).

 

Series A Convertible Preferred Shares and Derivative Liability

 

When the Company issues the Series A convertible preferred shares (see NOTE 12), it first evaluates the balance sheet classification of the convertible instrument in its entirety to determine whether the instrument should be classified as a liability under ASC Topic 480, “Distinguishing Liabilities from Equity”, and second evaluates whether the conversion feature should be accounted for separately from the host instrument. A conversion feature of the Series A convertible preferred shares would be separated from the convertible instrument and classified as a derivative liability if the conversion feature, as a standalone instrument, meets the definition of an embedded derivative under ASC Topic 815, “Derivatives and Hedging”. Generally, characteristics that require derivative treatment include, among others, when the conversion feature is not indexed to the Company’s equity, as defined in ASC Topic 815-40, or when it must be settled either in cash or by issuing equity shares that are readily convertible to cash.

 

The Company assesses the Series A convertible preferred shares as a whole and determines it does not meet the liability classification pursuant to ASC Topic 480 and the Company classifies the host instrument as permanent equity because no features provide for redemption by the holders of the Series A convertible preferred shares or conditional redemption, which is not solely within the Company’s control, and there are no unconditional obligations in that (i) the Company must or may settle in a variable number of its equity shares, and (ii) the monetary value is predominantly fixed, varying with something other than the fair value of the Company’s equity shares or varying inversely in relation to the Company’s equity shares.

 

The Company assesses the conversion feature of the Series A convertible preferred shares for derivative accounting consideration and determines it meets the definition of an embedded derivative, which is separated from the host instrument and classified as a derivative liability carried on the consolidated balance sheets at fair value with any changes in fair value recognized in other income (expenses). The Company values the fair value of derivative liability using the income approach with the discounted cash flow valuation method with the assistance of a third-party valuation appraiser. The determination of fair value requires management to make significant estimates and assumptions related to forecasted cash flows and discount rate.

 

Fair Value Measurements

 

The Company performs fair value measurements in accordance with ASC Topic 820, “Fair Value Measurements and Disclosures”. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset’s or a liability’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC Topic 820 establishes three levels of inputs that may be used to measure fair value:

 

  ● Level 1: quoted prices in active markets for identical assets or liabilities;
  ● Level 2: inputs other than Level 1 that are observable, either directly or indirectly; or
  ● Level 3: unobservable inputs that are supported by little or no market activities and that are significant to the fair values of the assets or liabilities.

 

As of September 30, 2026 and December 31, 2025, the carrying values of current assets, except for investments in marketable securities, and current liabilities, except for derivative liability, approximated their fair values reported in the consolidated balance sheets due to the short-term maturities of these instruments.

 

F-10
 

 

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025 are summarized below (also see NOTE 5 for investments):

 

             
Fair Value Measurements as of September 30, 2026
   Quoted Prices
in Active
Markets for Identical
Assets or Liabilities
(Level 1)
   Significant Other
Observable
Inputs
(Level 2)
   Unobservable
Inputs
(Level 3)
   Fair Value at
September 30, 2026
 
Investments in marketable securities  $1,380,553   $-   $-   $1,380,553 
Long-term investment in warrants  $-   $130,916   $-   $130,916 
Derivative liability  $-   $-   $62,507   $62,507 

 

             
Fair Value Measurements as of December 31, 2025
  

Quoted Prices

in Active

Markets for Identical

Assets or Liabilities

(Level 1)

   Significant Other
Observable
Inputs
(Level 2)
   Unobservable
Inputs
(Level 3)
   Fair Value at
December 31, 2025
 
Investments in marketable securities  $3,690,187   $-   $-   $3,690,187 
Long-term investment in warrants  $-   $280,924   $-   $280,924 
Derivative liability  $-   $-   $121,719   $121,719 

 

The following table summarizes the changes in derivative liability for the nine months ended September 30, 2026 and 2025 for which the Company used Level 3 inputs to determine fair value:

         
   For the Nine Months 
   Ended September 30, 
   2026   2025 
Fair value of derivative liability at beginning of the period  $121,719   $- 
Derivative liability recognized upon issuance of Series A convertible preferred shares   -    236,141 
Changes in fair value of derivative liability   630    9,679 
Derivative liability extinguished upon conversion of Series A convertible preferred shares   (59,842)   - 
Fair value of derivative liability at end of the period  $62,507   $245,820 

 

The valuation of derivative liability is determined using the discounted cash flow valuation method. The discount rate used to determine derivative liability as of September 30, 2026 and December 31, 2025 are 19% and 19%, respectively.

 

Assets Held for Sale and Discontinued Operations

 

In accordance with ASC Topic 205-20, “Presentation of Financial Statements – Discontinued Operations”, a component or a group of components of an entity shall be classified as held for sale in the period in which all of the following criteria are met: (i) management, having the authority to approve the action, commits to a plan to sell the entity to be sold; (ii) the entity to be sold is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such entities to be sold; (iii) an active program to locate a buyer or buyers and other actions required to complete the plan to sell the entity to be sold have been initiated; (iv) the sale of the entity to be sold is probable and transfer of the entity to be sold is expected to qualify for recognition as a completed sale within one year; (v) the entity to be sold is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and (vi) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. A component or a group of components of an entity classified as held for sale is reported at the lower of its carrying amount or fair value less cost to sell. If the fair value of the entity to be sold less cost to sell is lower than its carrying amount, an impairment loss is recognized and update each reporting period as appropriate. Assets held for sale are not depreciated or amortized.

 

The results of operations of the entity to be sold classified as held for sale are reported as discontinued operations if the disposal represents a strategic shift that has or will have a major effect on an entity’s operations and financial results.

 

The Company assesses the sales of HeartCore Japan, Sigmaways and its wholly-owned subsidiaries and HeartCore Luvina and determines they meet the held for sale criteria and the discontinued operations criteria. The assets and liabilities of Sigmaways and its wholly-owned subsidiaries and HeartCore Luvina have been reflected as assets and liabilities of discontinued operations in the consolidated balance sheets for all periods presented. The results of operations of HeartCore Japan, Sigmaways and its wholly-owned subsidiaries and HeartCore Luvina are presented as discontinued operations in the unaudited consolidated statements of operations and comprehensive income (loss) for all periods presented. Prior periods have been adjusted to conform to the current presentation. The required disclosures are included in NOTE 14.

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued Accounting Standards Update (“ASU”) No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public companies to disclose additional information about specific expense categories in the notes to the consolidated financial statements on an annual and interim basis. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.

 

F-11
 

 

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU No. 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its unaudited interim consolidated financial statements and related disclosures.

 

NOTE 3 – REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

 

In connection with the preparation of the unaudited consolidated financial statements for the three and nine months ended September 30, 2026, the Company identified certain adjustments to the Company’s previously issued consolidated financial statements as of and for the years ended December 31, 2025 and 2024, as well as its unaudited interim consolidated financial statements as of and for the three months ended March 31, 2026, as of and for the three and six months ended June 30, 2026, and the unaudited consolidated balance sheets and unaudited consolidated statements of changes in shareholders’ equity as of and for the three and nine months ended September 30, 2025, as of and for the three and six months ended June 30, 2025, and as of and for the three months ended March 31, 2025 relating to miscalculations of income tax payables, income tax expense (benefit) and deferred tax liabilities.

 

In accordance with Staff Accounting Bulletin (“SAB”) No. 99, Materiality, and SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, the Company evaluated the adjustments from qualitative and quantitative perspectives under both iron curtain and rollover methods, and determined that the impact was not material to the results of operations or financial position as presented in the Company’s quarterly and annual financial statements that have been previously filed in the Company’s Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. As a result, amendment of such reports is not required. The Company decided to revise the previously issued consolidated financial statements as of and for the year ended December 31, 2025, and unaudited interim consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows for the three months ended March 31, 2026 and for the three and six months ended June 30, 2026 in this filing. There were no changes to the unaudited consolidated statements of changes in shareholders’ equity for the three and nine months ended September 30, 2025, for the three and six months ended June 30, 2025, and for the three months ended March 31, 2025 except for the effects of the changes related to the opening accumulated deficit as of January 1, 2025 described below. The Company will revise the previously issued unaudited consolidated balance sheets as of June 30, 2026, March 31, 2026, September 30, 2025, June 30, 2025 and March 31, 2025 in future filings as applicable.

 

Due to certain adjustments originating prior to the year ended December 31, 2025, the opening accumulated deficit as of January 1, 2025 was overstated by $687,469, relating to the impact of income tax benefit that should have been recorded in the year ended December 31, 2024.

 

All prior periods have been adjusted to conform to the current presentations for the discontinued operations relating to the sales of HeartCore Japan, Sigmaways and its wholly-owned subsidiaries and HeartCore Luvina. In connection with the revision, the Company also corrected other previously identified immaterial adjustments.

 

Revision of Consolidated Financial Statements

 

The following table reconciles the selected financial information with respect to the Company’s consolidated balance sheet as of December 31, 2025 from the previously reported amounts to the revised amounts:

  

          
   As of December 31, 2025 
   As Reported   Adjustment   As Revised 
Income tax payables  $1,830,228   $(1,829,190)  $1,038 
Total current liabilities   5,330,250    (1,829,190)   3,501,060 
Deferred tax liabilities   -    1,039,181    1,039,181 
Total non-current liabilities   448,376    1,039,181    1,487,557 
Total liabilities   5,778,626    (790,009)   4,988,617 
Accumulated deficit   (13,755,534)   790,009    (12,965,525)
Total HeartCore Enterprises, Inc. shareholders’ equity   8,780,123    790,009    9,570,132 
Total shareholders’ equity   7,282,851    790,009    8,072,860 

 

The following table reconciles the selected financial information with respect to the Company’s consolidated statement of operations and comprehensive income for the year ended December 31, 2025 from the previously reported amounts to the revised amounts:

 

          
   For the Year Ended December 31, 2025 
   As Reported   Adjustment   As Revised 
Income tax expense (benefit)  $11,511   $(1,277,463)  $(1,265,952)
Net loss from continuing operations   (3,439,682)   1,277,463    (2,162,219)
Income from discontinued operations, net of income tax   8,932,970    (1,174,923)   7,758,047 
Net income   5,493,288    102,540    5,595,828 
Net income attributable to HeartCore Enterprises, Inc.   5,793,884    102,540    5,896,424 
Net income attributable to HeartCore Enterprises, Inc. common shareholders   5,699,527    102,540    5,802,067 
Total comprehensive income   5,085,661    102,540    5,188,201 
Comprehensive income attributable to HeartCore Enterprises, Inc.   5,391,451    102,540    5,493,991 
                
Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share*               
Basic  $(3.06)  $1.11   $(1.96)
Diluted  $(3.06)  $1.11   $(1.96)
                
Income from discontinued operations per common share*               
Basic  $8.00   $(1.02)  $6.99 
Diluted  $8.00   $(1.02)  $6.99 
                
Net income attributable to HeartCore Enterprises, Inc. per common share*               
Basic  $4.94   $0.09   $5.03 
Diluted  $4.94   $0.09   $5.03 

 

*On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company’s issued and outstanding common shares. References to per share information of common shares have been retroactively adjusted. See NOTE 12.

 

F-12
 

 

The following table reconciles the selected financial information with respect to the Company’s consolidated statement of changes in shareholders’ equity for the year ended December 31, 2025 from the previously reported amounts to the revised amounts:

 

   Accumulated Deficit   Total HeartCore Enterprises, Inc. Shareholders’ Equity  

Total

Shareholders’ Equity

       Accumulated Deficit   Total HeartCore Enterprises, Inc. Shareholders’ Equity  

Total

Shareholders’ Equity

 
   As Reported   As Reported   As Reported   Adjustment   As Revised   As Revised   As Revised 
Balance, January 1, 2025  $(16,244,843)  $4,653,497   $3,462,015   $687,469   $(15,557,374)  $5,340,966   $4,149,484 
Net income   5,793,884    5,793,884    5,493,288    102,540    5,896,424    5,896,424    5,595,828 
Balance, December 31, 2025  $(13,755,534)  $8,780,123   $7,282,851   $790,009   $(12,965,525)  $9,570,132   $8,072,860 

 

The following table reconciles the selected financial information with respect to the Company’s consolidated statement of cash flows for the year ended December 31, 2025 from the previously reported amounts to the revised amounts:

 

          
   For the Year Ended December 31, 2025 
   As Reported   Adjustment   As Revised 
Cash flows from operating activities of continuing operations:               
Net income  $5,493,288   $102,540   $5,595,828 
Income from discontinued operations, net of income tax   8,932,970    (1,174,923)   7,758,047 
Net loss from continuing operations   (3,439,682)   1,277,463    (2,162,219)
Adjustments to reconcile net loss from continuing operations to net cash flows used in operating activities of continuing operations:               
Deferred income taxes   9,192    (292,378)   (283,186)
Changes in assets and liabilities:               
Income tax payables   1,032,023    (985,085)   46,938 
Net cash flows used in operating activities of continuing operations  $(2,712,902)  $-   $(2,712,902)

 

The following summary reconciles the selected financial information with respect to the Company’s disclosures of income taxes as of and for the year ended December 31, 2025 from the previously reported amounts to the revised amounts:

 

For the year ended December 31, 2025, the Company’s income tax expense (benefit) are as follows:

 

   As Reported   Adjustment   As Revised 
   For the Year Ended December 31, 2025 
   As Reported   Adjustment   As Revised 
Current  $2,319   $(985,085)  $(982,766)
Deferred   9,192    (292,378)   (283,186)
Income tax expense (benefit)  $11,511   $(1,277,463)  $(1,265,952)

 

After the adoption of ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, on a prospective basis, a reconciliation of the provision for income taxes to the amount computed by applying the 21% U.S. federal statutory income tax rate to loss from continuing operations before income tax expense (benefit) for the year ended December 31, 2025 is as follows:

 

                               
   For the Year Ended December 31, 2025 
   Amount   Percent 
   As Reported   Adjustment   As Revised   As Reported   Adjustment   As Revised 
Tax at U.S. federal statutory rate  $(719,916)  $-   $(719,916)   21.00%   0.00%   21.00%
State and local income tax, net of federal income tax effect   (235,516)   -    (235,516)   6.87%   0.00%   6.87%
Foreign tax effects:                              
Other foreign jurisdictions   (128)   -    (128)   0.00%   0.00%   0.00%
Effect of expenses not deductible for tax purpose   7,807    -    7,807    (0.23)%   0.00%   (0.23)%
Change in valuation allowance   956,082    (1,282,026)   (325,944)   (27.89)%   37.40%   9.51%
Other adjustments   3,182    4,563    7,745    (0.09)%   (0.13)%   (0.22)%
Effective income tax rate  $11,511   $(1,277,463)  $(1,265,952)   (0.34)%   37.27%   36.93%

 

F-13
 

 

The tax effects of temporary differences that give rise to the deferred tax assets and liabilities at December 31, 2025 are presented below:

 

          
   As of December 31, 2025 
   As Reported   Adjustment   As Revised 
Deferred tax assets               
Revenue adjustments  $738,020   $(738,020)  $- 
Expense adjustments   29,286    (6,165)   23,121 
Fair value change on investment securities   130,078    (130,078)   - 
Net operating losses carried forward   1,280,818    (1,280,818)   - 
Total deferred tax assets, gross   2,178,202    (2,155,081)   23,121 
Less: valuation allowance   (2,129,401)   2,129,401    - 
Total deferred tax assets, net  $48,801   $(25,680)  $23,121 
                
Deferred tax liabilities               
Fair value change on derivative liability  $(25,680)  $25,680   $- 
Installment sale gain deferral   -    (1,039,181)   (1,039,181)
Total deferred tax liabilities  $(25,680)  $(1,013,501)  $(1,039,181)
                
Deferred tax assets  $23,121   $-   $23,121 
Deferred tax liabilities  $-   $(1,039,181)  $(1,039,181)

 

The following summary reconciles the selected financial information with respect to the Company’s disclosures of discontinued operations for HeartCore Japan for the year ended December 31, 2025 from the previously reported amounts to the revised amounts:

 

The following table summarizes the results of operations from discontinued operations, net of income tax for HeartCore Japan in the consolidated statements of operations and comprehensive income for the year ended December 31, 2025:

 

          
   For the Year Ended December 31, 2025 
   As Reported   Adjustment   As Revised 
Income from discontinued operations before income tax expense  $10,855,906   $-   $10,855,906 
Income tax expense   1,178,613    1,174,923    2,353,536 
Income from discontinued operations, net of income tax  $9,677,293   $(1,174,923)  $8,502,370 

 

Revision of Unaudited Interim Consolidated Financial Statements

 

The following table reconciles the selected financial information with respect to the Company’s unaudited consolidated statement of operations and comprehensive loss for the three months ended March 31, 2026 from the previously reported amounts to the revised amounts:

 

   As Reported   Adjustment   As Revised 
   For the Three Months Ended March 31, 2026 
   As Reported   Adjustment   As Revised 
Income tax expense (benefit)  $10,171   $(409,057)  $(398,886)
Net loss from continuing operations   (1,762,414)   409,057    (1,353,357)
Net loss   (1,976,715)   409,057    (1,567,658)
Net loss attributable to HeartCore Enterprises, Inc.   (1,871,707)   409,057    (1,462,650)
Net loss attributable to HeartCore Enterprises, Inc. common shareholders   (1,899,675)   409,057    (1,490,618)
Total comprehensive loss   (1,992,855)   409,057    (1,583,798)
Comprehensive loss attributable to HeartCore Enterprises, Inc.   (1,879,309)   409,057    (1,470,252)
                
Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share*               
Basic  $(1.41)  $0.32   $(1.09)
Diluted  $(1.41) 

$

0.32   $(1.09)
                
Net loss attributable to HeartCore Enterprises, Inc. per common share*               
Basic  $(1.49)  $0.32   $(1.17)
Diluted  $(1.49)  $0.32   $(1.17)

 

* On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company’s issued and outstanding common shares. References to per share information of common shares have been retroactively adjusted. See NOTE 12.

 

F-14
 

 

The following table reconciles the selected financial information with respect to the Company’s unaudited consolidated statement of changes in shareholders’ equity for the three months ended March 31, 2026 from the previously reported amounts to the revised amounts:

 

                             
   Accumulated Deficit   Total HeartCore Enterprises, Inc. Shareholders’ Equity   Total Shareholders’ Equity       Accumulated Deficit   Total HeartCore Enterprises, Inc. Shareholders’ Equity   Total Shareholders’ Equity 
   As Reported   As Reported   As Reported   Adjustment   As Revised   As Revised   As Revised 
Balance, January 1, 2026  $(13,755,534)  $8,780,123   $7,282,851   $790,009   $(12,965,525)  $9,570,132   $8,072,860 
Net loss   (1,871,707)   (1,871,707)   (1,976,715)   409,057    (1,462,650)   (1,462,650)   (1,567,658)
Balance, March 31, 2026  $(15,627,241)  $6,874,877   $5,264,059   $1,199,066   $(14,428,175)  $8,073,943   $6,463,125 

 

The following table reconciles the selected financial information with respect to the Company’s unaudited consolidated statement of cash flows for the three months ended March 31, 2026 from the previously reported amounts to the revised amounts:

 

             
   For the Three Months Ended March 31, 2026 
   As Reported   Adjustment   As Revised 
Cash flows from operating activities of continuing operations:               
Net loss  $(1,976,715)  $409,057   $(1,567,658)
Loss from discontinued operations, net of income tax   (214,301)   -    (214,301)
Net loss from continuing operations   (1,762,414)   409,057    (1,353,357)
Adjustments to reconcile net loss from continuing operations to net cash flows used in operating activities of continuing operations:               
Deferred income taxes   -    (409,057)   (409,057)
Net cash flows used in operating activities of continuing operations  $(1,085,689)  $-   $(1,085,689)

 

The following summary reconciles the selected financial information with respect to the Company’s disclosures of income taxes for the three months ended March 31, 2026 from the previously reported amounts to the revised amounts:

 

For the three months ended March 31, 2026, the Company’s income tax expense (benefit) and effective tax rate are as follows:

 

             
   For the Three Months Ended March 31, 2026 
   As Reported   Adjustment   As Revised 
Current  $10,171   $-   $10,171 
Deferred   -    (409,057)   (409,057)
Income tax expense (benefit)  $10,171   $(409,057)  $(398,886)
                
Effective tax rate   (0.58)%   23.34%   22.76%

 

The following table reconciles the selected financial information with respect to the Company’s unaudited consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2026 from the previously reported amounts to the revised amounts:

 

                   
   For the Three Months Ended June 30, 2026   For the Six Months Ended June 30, 2026 
   As Reported   Adjustment   As Revised   As Reported   Adjustment   As Revised 
Income tax expense (benefit)  $12,826   $(356,167)  $(343,341)  $22,997   $(765,224)  $(742,227)
Net loss from continuing operations   (1,582,473)   356,167    (1,226,306)   (3,344,887)   765,224    (2,579,663)
Loss from discontinued operations, net of income tax   (457,046)   54,786    (402,260)   (671,347)   54,786    (616,561)
Net loss   (2,039,519)   410,953    (1,628,566)   (4,016,234)   820,010    (3,196,224)
Net loss attributable to HeartCore Enterprises, Inc.   (2,023,080)   410,953    (1,612,127)   (3,894,787)   820,010    (3,074,777)
Net loss attributable to HeartCore Enterprises, Inc. common shareholders   (2,042,436)   410,953    (1,631,483)   (3,942,111)   820,010    (3,122,101)
Total comprehensive loss   (1,976,521)   410,953    (1,565,568)   (3,969,376)   820,010    (3,149,366)
Comprehensive loss attributable to HeartCore Enterprises, Inc.   (1,959,683)   410,953    (1,548,730)   (3,838,992)   820,010    (3,018,982)
                               
Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share                              
Basic  $(1.14)  $0.25   $(0.88)  $(2.53)  $0.57   $(1.96)
Diluted  $(1.14)  $0.25   $(0.88)  $(2.53)  $0.57   $(1.96)
                               
Loss from discontinued operations per common share                              
Basic  $(0.31)  $0.04   $(0.27)  $(0.41)  $0.04   $(0.37)
Diluted  $(0.31)  $0.04   $(0.27)  $(0.41)  $0.04   $(0.37)
                               
Net loss attributable to HeartCore Enterprises, Inc. per common share                              
Basic  $(1.45)  $0.29   $(1.16)  $(2.94)  $0.61   $(2.33)
Diluted  $(1.45)  $0.29   $(1.16)  $(2.94)  $0.61   $(2.33)

 

F-15
 

 

The following table reconciles the selected financial information with respect to the Company’s unaudited consolidated statement of changes in shareholders’ equity for the three and six months ended June 30, 2026 from the previously reported amounts to the revised amounts:

 

   Accumulated Deficit   Total HeartCore Enterprises, Inc. Shareholders’ Equity  

Total

Shareholders’ Equity

       Accumulated Deficit   Total HeartCore Enterprises, Inc. Shareholders’ Equity  

Total

Shareholders’ Equity

 
   As Reported   As Reported   As Reported   Adjustment   As Revised   As Revised   As Revised 
Balance, January 1, 2026  $(13,755,534)  $8,780,123   $7,282,851   $790,009   $(12,965,525)  $9,570,132   $8,072,860 
Net loss   (1,871,707)   (1,871,707)   (1,976,715)   409,057    (1,462,650)   (1,462,650)   (1,567,658)
Balance, March 31, 2026   (15,627,241)   6,874,877    5,264,059    1,199,066    (14,428,175)   8,073,943    6,463,125 
Net loss   (2,023,080)   (2,023,080)   (2,039,519)   410,953    (1,612,127)   (1,612,127)   (1,628,566)
Balance, June 30, 2026  $(17,650,321)  $4,895,838   $5,066,630   $1,610,019   $(16,040,302)  $6,505,857   $6,676,649 

 

The following table reconciles the selected financial information with respect to the Company’s unaudited consolidated statement of cash flows for the six months ended June 30, 2026 from the previously reported amounts to the revised amounts:

 

          
   For the Six Months Ended June 30, 2026 
   As Reported   Adjustment   As Revised 
Cash flows from operating activities of continuing operations:               
Net loss  $(4,016,234)  $820,010   $(3,196,224)
Loss from discontinued operations, net of income tax   (671,347)   54,786    (616,561)
Net loss from continuing operations   (3,344,887)   765,224    (2,579,663)
Adjustments to reconcile net loss from continuing operations to net cash flows used in operating activities of continuing operations:               
Deferred income taxes   -    (765,224)   (765,224)
Net cash flows used in operating activities of continuing operations  $(2,360,468)  $-   $(2,360,468)

 

The following summary reconciles the selected financial information with respect to the Company’s disclosures of income taxes for the three and six months ended June 30, 2026 from the previously reported amounts to the revised amounts:

 

For the three and six months ended June 30, 2026, the Company’s income tax expense (benefit) and effective tax rate are as follows:

 

                   
   For the Three Months Ended June 30, 2026   For the Six Months Ended June 30, 2026 
   As Reported   Adjustment   As Revised   As Reported   Adjustment   As Revised 
Current  $12,826   $-   $12,826   $22,997   $-   $22,997 
Deferred   -    (356,167)   (356,167)   -    (765,224)   (765,224)
Income tax expense (benefit)  $12,826   $(356,167)  $(343,341)  $22,997   $(765,224)  $(742,227)
                               
Effective tax rate   (0.82)%   22.69%   21.87%   (0.69)%   23.04%   22.34%

 

The following summary reconciles the selected financial information with respect to the Company’s disclosures of discontinued operations for Sigmaways and its wholly-owned subsidiaries for the three and six months ended June 30, 2026 from the previously reported amounts to the revised amounts:

 

The following table summarizes the results of operations from discontinued operations, net of income tax for Sigmaways and its wholly-owned subsidiaries in the unaudited consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2026:

 

                         
   For the Three Months Ended June 30, 2026   For the Six Months Ended June 30, 2026 
   As Reported   Adjustment   As Revised   As Reported   Adjustment   As Revised 
Loss from discontinued operations before income tax expense (benefit)  $(489,125)  $-   $(489,125)  $(732,618)  $-   $(732,618)
Income tax expense (benefit)   105    (54,786)   (54,681)   105    (54,786)   (54,681)
Loss from discontinued operations, net of income tax   (489,230)   54,786    (434,444)   (732,723)   54,786    (677,937)
Less: loss from discontinued operations attributable to non-controlling interests   (32,209)   -    (32,209)   (151,521)   -    (151,521)
Loss from discontinued operations attributable to HeartCore Enterprises, Inc.  $(457,021)  $54,786   $(402,235)  $(581,202)  $54,786   $(526,416)

 

NOTE 4 – RELATED PARTY TRANSACTIONS

 

As of September 30, 2026 and December 31, 2025, the Company had due to related party balances of $423 and $285, respectively, from Sumitaka Yamamoto, the Chief Executive Officer (“CEO”) and major shareholder of the Company. The balance is unsecured, non-interest bearing and due on demand. During the nine months ended September 30, 2026 and 2025, the related party paid operating expenses on behalf of the Company and received the payments in a net amount of $138 and nil, respectively.

 

On August 3, 2026, the Company entered into a purchase agreement to sell 51% of the outstanding shares of HeartCore Luvina to Luvina Software Joint Stock Company (“Luvina Software”), the non-controlling shareholder of HeartCore Luvina. On August 17, 2026, the sale transaction was closed. See NOTE 14.

 

F-16
 

 

NOTE 5 – INVESTMENTS

 

Investment in Warrants

 

The Company received warrants from its customers as noncash consideration from consulting services. The warrants are not registered for public sale and are initially measured at fair value at contract inception. The Company’s investment in warrants is measured on a recurring basis and carried on the consolidated balance sheets at an estimated fair value at the end of the period. The valuation of investment in warrants is determined using the Black-Scholes model based on the stock price, exercise price, expected volatility, time to maturity and risk-free interest rate for the term of the warrants.

 

The following table summarizes the Company’s investment in warrants activities for the nine months ended September 30, 2026 and 2025:

  

   2026   2025 
   For the Nine Months 
   Ended September 30, 
   2026   2025 
Fair value of investment in warrants at beginning of the period  $280,924   $577,786 
Warrants received as noncash consideration   -    837,913 
Changes in fair value of investment in warrants   (7,493)   (74,109)
Warrants converted to marketable securities*   (142,515)   (388,260)
Fair value of investment in warrants at end of the period  $130,916   $953,330 

 

Investments in Marketable Securities

 

The Company’s investments in marketable securities represent stocks received from its customers as noncash consideration from consulting services and stocks received upon the exercise of warrants described above. They are registered for public sale with readily determinable fair values, and are measured at quoted prices on a recurring basis at the end of the period.

 

The following table summarizes the Company’s investments in marketable securities activities for the nine months ended September 30, 2026 and 2025:

 

   2026   2025 
   For the Nine Months 
   Ended September 30, 
   2026   2025 
Fair value of investments in marketable securities at beginning of the period  $3,690,187   $4,495,703 
Marketable securities converted from warrants*   142,515    388,260 
Changes in fair value of investments in marketable securities   (375,367)   (908,416)
Marketable securities sold   (2,076,782)   (1,071,732)
Fair value of investments in marketable securities at end of the period  $1,380,553   $2,903,815 

 

* For the nine months ended September 30, 2026 and 2025, the Company exercised 63,558 and 190,674 shares of warrants in exchange for 63,558 and 190,674 shares of common shares, respectively.

 

NOTE 6 – PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consist of the following:

  

   September 30,   December 31, 
   2026   2025 
Machinery and equipment  $271,957   $268,319 
Vehicle   81,016    81,420 
Subtotal   352,973    349,739 
Less: accumulated depreciation   (97,101)   (74,274)
Total property and equipment, net  $255,872   $275,465 

 

For the three and nine months ended September 30, 2026, the Company recognized depreciation expenses of $7,629 and $23,023, respectively. For the three and nine months ended September 30, 2025, the Company recognized depreciation expenses of $8,265 and $36,994, respectively.

 

NOTE 7 – LEASES

 

The Company has entered into operating leases for office space with terms ranging from two to three years, and finance lease for vehicle with term of five years. The estimated effect of lease renewal and termination options, as applicable, that are reasonably certain to be exercised in the determination of the lease term and initial measurement of lease right-of-use assets and lease liabilities is included in the unaudited consolidated financial statements.

 

Operating leases costs for lease payments are recognized on a straight-line basis over the lease term. Finance lease costs include amortization, which is recognized on a straight-line basis over the expected life of the leased asset, and interest expense, which is recognized following an effective interest rate method. Leases with initial term of twelve months or less are not recorded in the consolidated balance sheets.

 

The components of lease costs for the three and nine months ended September 30, 2026 and 2025 are as follows:

  

   2026   2025   2026   2025 
   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2026   2025   2026   2025 
Finance lease costs                    
Amortization of finance lease right-of-use assets  $-   $4,353   $-   $12,841 
Interest on finance lease liabilities   -    178    -    566 
Total finance lease costs   -    4,531    -    13,407 
Operating leases costs   68,213    4,419    201,385    30,946 
Total leases costs  $68,213   $8,950   $201,385   $44,353 

 

F-17
 

 

The following table presents supplemental information related to the Company’s leases for the nine months ended September 30, 2026 and 2025:

  

   2026   2025 
   For the Nine Months 
   Ended September 30, 
   2026   2025 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows from finance lease  $-   $566 
Operating cash flows from operating leases   195,372    21,067 
Financing cash flows from finance lease   -    12,692 
Operating lease right-of-use assets obtained in exchange for operating lease liabilities   552,577    23,495 
           
Weighted average remaining lease term (years):          
Finance lease   -    3.0 
Operating leases   1.3    2.5 
           
Weighted average discount rate (per annum):          
Finance lease   0.00%   1.32%
Operating leases   1.32%   1.32%

 

As of September 30, 2026, the future maturity of lease liabilities is as follows:

  

   Operating 
Year Ended December 31,  Leases 
Remaining of 2026  $72,022 
2027   288,087 
Total lease payments   360,109 
Less: imputed interest   (3,575)
Total lease liabilities   356,534 
Less: current portion   (284,622)
Non-current lease liabilities  $71,912 

 

Pursuant to the operating lease agreements, the Company made security deposits to the lessors. The security deposits amounted to $276,199 and $278,342 as of September 30, 2026 and December 31, 2025, respectively.

 

NOTE 8 – LONG-TERM LOAN RECEIVABLE

 

As of September 30, 2026 and December 31, 2025, the Company had a long-term loan receivable balance of $258,859 and nil, respectively, from an employee of the Company. The loan is occasionally made to the employee to assist the employee’s personal needs. The balance is unsecured, bears an annual interest of 1.3%, and matures on August 31, 2031.

 

NOTE 9 – OTHER CURRENT LIABILITIES

 

Other current liabilities consist of the following:

 

   September 30,   December 31, 
   2026   2025 
Customer refund liability*  $500,000   $500,000 
Others   30,070    21,607 
Total other current liabilities  $530,070   $521,607 

 

* On June 28, 2024, the Company entered into a settlement agreement with a customer, pursuant to which the consulting services agreement with the customer was terminated and the Company would refund $500,000 to the customer in August 2025. As of the date of this report, the Company did not make payment to the customer.

 

F-18
 

 

NOTE 10 – INCOME TAXES

 

United States

 

HeartCore USA and HeartCore Financial, incorporated in the United States, are subject to federal income tax at 21% statutory tax rate with respect to the profit generated from the United States.

 

Japan

 

HeartCore Financial – Japan and Higgs Field are companies incorporated in Japan. Income taxes in Japan are imposed by the national, prefectural and municipal governments, and in the aggregate result in an effective statutory tax rate of approximately 34.59%.

 

For the three and nine months ended September 30, 2026 and 2025, the Company’s income tax expense (benefit) are as follows:

  

   2026   2025   2026   2025 
   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2026   2025   2026   2025 
Current  $6,545   $32   $29,542   $3,697 
Deferred   (30,822)   2,007    (796,046)   29,680 
Income tax expense (benefit)  $(24,277)  $2,039   $(766,504)  $33,377 

 

For the three and nine months ended September 30, 2026, the effective tax rate were 4.09% and 19.58%, respectively. For the three and nine months ended September 30, 2025, the effective tax rate were 1.96% and (1.39)%, respectively.

 

NOTE 11 – STOCK-BASED COMPENSATION

 

On August 6, 2021, the Board of Directors and shareholders of the Company approved a 2021 Equity Incentive Plan (“2021 Plan”), under which 120,000 shares of common shares are authorized for issuance.

 

On August 1, 2023, the Board of Directors of the Company approved a 2023 Equity Incentive Plan (“2023 Plan”), under which 100,000 shares of common shares are authorized for issuance.

 

Stock Options

 

On December 25, 2021, the Company awarded stock options to purchase 76,725 shares of common shares pursuant to the 2021 Plan at an exercise price of $50.00 per share to various officers, directors, employees and consultants of the Company. The stock options vest on each annual anniversary of the date of issuance, in an amount equal to 25% of the applicable shares of common shares, with the expiration date on December 25, 2031.

 

On August 9, 2022, the Company awarded stock options to purchase 725 shares of common shares at an exercise price of $49.60 per share to three prior employees of the Company. The stock options are fully vested and exercisable on the grant date, with the expiration date on August 9, 2026.

 

On February 3, 2023, the Company awarded stock options to purchase 5,000 shares of common shares pursuant to the 2021 Plan at an exercise price of $23.40 per share to an employee of the Company. The stock options vest 50% on the grant date and February 1, 2024, respectively, with the expiration date on February 3, 2033.

 

F-19
 

 

The following table summarizes the stock options activities and related information for the nine months ended September 30, 2026 and 2025:

 

   Number of
Stock Options
   Weighted
Average
Exercise Price
   Weighted
Average
Remaining
Term (Years)
   Intrinsic
Value
 
As of January 1, 2025   75,325   $48.23    7.01   $64,500 
Granted   -    -    -    - 
Exercised   (5,000)          23.40    -    - 
Forfeited   (1,325)   50.00    -    - 
Expired   -    -    -    - 
As of September 30, 2025   69,000   $50.00    6.18   $- 
                     
As of January 1, 2026   56,075   $49.99    5.92   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Forfeited   -    -    -    - 
Expired   (725)   49.60    -    - 
As of September 30, 2026   55,350   $50.00    5.24   $- 
Vested and exercisable as of September 30, 2026   55,350   $50.00    5.24   $- 

 

For the three and nine months ended September 30, 2026, there was no stock-based compensation related to stock options. For the three and nine months ended September 30, 2025, the Company recognized stock-based compensation related to stock options of $3,032 and $55,714, respectively. There was no outstanding unamortized stock-based compensation related to stock options as of September 30, 2026.

 

Restricted Stock Units (“RSUs”)

 

On February 9, 2022, the Company entered into executive employment agreements with five executives and granted 4,291 RSUs pursuant to the 2021 Plan. The RSUs vest on each annual anniversary of the date of the employment agreements, in an amount equal to 25% of the applicable shares of common shares. The fair value of the RSUs at grant date is $424,809.

 

The following table summarizes the RSUs activities and related information for the nine months ended September 30, 2026 and 2025:

 

   Number of
RSUs
   Weighted Average
Grant Date
Fair Value
Per Share
 
Unvested as of January 1, 2025   2,146   $99.00 
Granted   -    - 
Vested   (1,073)   99.00 
Forfeited   (113)   99.00 
Unvested as of September 30, 2025   960   $99.00 
           
Unvested as of January 1, 2026   796   $99.00 
Granted   -    - 
Vested   (796)   99.00 
Forfeited   -    - 
Unvested as of September 30, 2026   -   $- 

 

For the three and nine months ended September 30, 2026, the Company recognized stock-based compensation related to RSUs of nil and $2,031, respectively. For the three and nine months ended September 30, 2025, the Company recognized stock-based compensation related to RSUs of $5,986 and $13,508, respectively. There was no outstanding unamortized stock-based compensation related to RSUs as of September 30, 2026.

 

F-20
 

 

NOTE 12 – SHAREHOLDERS’ EQUITY

 

Shares Authorized

 

The Company is authorized to issue 200,000,000 shares of common shares, par value of $0.0001 per share, and 20,000,000 shares of preferred shares, par value of $0.0001 per share.

 

At the Market Offering Agreement (“ATM Agreement”)

 

On October 23, 2023, the Company entered into an ATM Agreement with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common shares, par value of $0.0001 per share, having an aggregate offering price of up to approximately $2 million (“ATM Shares”). The Company pays commission fees of 4% for each completed sale of ATM Shares pursuant to the terms of the ATM Agreement. For the nine months ended September 30, 2026 and 2025, the Company sold a total of nil and 794 shares of the ATM Shares for net proceeds of nil and $30,445 after deducting commission fees and other transaction costs, respectively. The subscription receivable of $103,942 related to ATM Shares sold on December 31, 2024 was collected in full on January 2, 2025.

 

Designation of Series A Convertible Preferred Shares and Securities Purchase Agreement

 

On June 30, 2025, the Company filed a certificate of designations of preferences and rights of Series A convertible preferred shares (“Series A COD”) with the Secretary of State of the State of Delaware to set forth the terms of the Series A convertible preferred shares. Pursuant to the Series A COD, the Company designated 2,000 shares of preferred shares as Series A convertible preferred shares and each share of Series A convertible preferred shares has a stated value of $1,100. On October 22, 2025, the Board of Directors of the Company approved to amend the number of designated shares of Series A convertible preferred shares to 4,000 shares pursuant to the Series A COD. The following summarizes the material terms of the Series A convertible preferred shares:

 

  ● Dividends – Each Series A convertible preferred shares holder (“Holder”) shall be entitled to receive dividends of 10% per annum on the stated value of each share of Series A convertible preferred shares.
     
  ● Liquidation – In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the Holders shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of common shares and any other class or series of equity shares of the Company, an amount per share equal to the greater of (i) the stated value plus all accrued and unpaid dividends thereon or (ii) the amount that such Holder would receive if such Holder converts all of its shares of Series A convertible preferred shares into common shares immediately prior to such liquidation, dissolution or winding up. If, upon any such liquidation, dissolution or winding up, the assets and funds available for distribution among the Holders shall be insufficient to permit the payment to such Holders of the full preferential amount aforesaid, then the entire assets and funds of the Company legally available for distribution shall be distributed ratably among the Holders in proportion to the amount that each such Holder is entitled to receive. After the payment of the full amount of the liquidation preference to which the Holders are entitled, the Holders shall have no right or claim to any of the remaining assets of the Company.
     
  ● Voting – The Series A convertible preferred shares shall have no voting rights. However, as long as any shares of Series A convertible preferred shares are outstanding, the Company shall not, without the affirmative vote of the Holders of a majority of the outstanding shares of Series A convertible preferred shares, and with each share of Series A convertible preferred shares having one vote on (i) alter or change adversely the powers, preferences or rights given to the Series A convertible preferred shares or alter or amend the Series A COD, (ii) issue additional shares of Series A convertible preferred shares or increase or decrease (other than by conversion) the number of authorized shares of Series A convertible preferred shares, or (iii) enter into any agreement with respect to any of the foregoing.
     
  ● Conversion – Each Holder shall have the right, at such Holder’s option, to convert any or all of the Series A convertible preferred shares held by such Holder into fully paid and nonassessable shares of common shares. The number of shares of common shares issuable upon conversion of each share of Series A convertible preferred shares shall be equal to the quotient obtained by dividing (i) the stated value plus all accrued and unpaid dividends thereon by (ii) 90% of the average of the two lowest volume weighted average price (“VWAP”) of the Company’s common shares for the five trading days immediately preceding the respective common shares conversion notice delivery date.
     
  ● Redemption – No share of Series A convertible preferred shares shall be redeemable under any circumstances.

 

F-21
 

 

On June 30, 2025, the Company entered into a securities purchase agreement and a registration rights agreement with Crom Structured Opportunities Fund I, LP (“Crom Structured”), pursuant to which the Company closed, issued and sold to Crom Structured an aggregate of 2,000 shares of the Company’s designated Series A convertible preferred shares for an aggregate purchase price of $2,000,000. Concurrently with the signing of the securities purchase agreement, the Company issued 37,500 shares of common shares (“37,500 Common Shares”) to Crom Structured for no consideration. The Company received net proceeds of $1,800,000 from the securities purchase agreement after deducting share issuance transaction fees. The net proceeds from the securities purchase agreement were allocated to Series A convertible preferred shares and 37,500 Common Shares based on their relative fair values.

 

For the three and nine months ended September 30, 2026, there were 100 and 500 shares of Series A convertible preferred shares converted into 49,077 and 201,830 shares of common shares, respectively. For the three and nine months ended September 30, 2025, no shares of Series A convertible preferred shares were converted into common shares.

 

For the three and nine months ended September 30, 2026, the Company paid dividends on Series A convertible preferred shares of $67,870 and $67,870 through issuance of 24,686 and 24,686 shares of common shares, respectively. For the three and nine months ended September 30, 2025, no dividends were paid on Series A convertible preferred shares.

 

For the three and nine months ended September 30, 2026, dividends accrued on Series A convertible preferred shares amounted to $15,206 and $62,530, respectively. For the three and nine months ended September 30, 2025, dividends accrued on Series A convertible preferred shares amounted to $56,222 and $56,833, respectively.

 

Equity Purchase Agreement

 

On June 30, 2025, the Company entered into an equity purchase agreement and a registration rights agreement with Crom Structured, pursuant to which Crom Structured has committed to purchase up to $25 million in shares of the Company’s common shares, subject to certain limitations and conditions set forth in the equity purchase agreement. The Company shall not issue or sell any shares of common shares under the equity purchase agreement which, when aggregate with all purchases of common shares made by Crom Structured pursuant to the equity purchase agreement, would result in beneficial ownership of more than 4.99% of the Company’s outstanding shares of common shares.

 

Pursuant to the terms of the equity purchase agreement, the Company has the right, but not the obligation, to sell to Crom Structured, shares of common shares over the period commencing on the date of the equity purchase agreement and ending on the earlier of (i) the date on which Crom Structured shall have purchased common shares pursuant to the equity purchase agreement equal to $25 million, (ii) June 30, 2027, (iii) written notice of termination by the Company to Crom Structured, (iv) the registration statement is no longer effective after the initial effective date of the registration statement, or (v) the date that the Company commences a voluntary bankruptcy case, a bankruptcy proceeding is commenced against the Company, a custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors. The purchase price will be calculated as 96% of the VWAP of the Company’s common shares on the trading day immediately preceding the respective common shares purchase notice delivery date.

 

Concurrently with the signing of the equity purchase agreement, the Company issued 24,272 shares of common shares to Crom Structured as a commitment fee. The total fair value of the common shares issued for the commitment fee of $250,000 was recorded as deferred offering costs in the consolidated balance sheets.

 

For the three and nine months ended September 30, 2026 and 2025, no common shares were sold pursuant to the terms of the equity purchase agreement.

 

Share Repurchase Program for Common Shares

 

On February 18, 2026, the Board of Directors of the Company approved a share repurchase program (“2026 Share Repurchase Program”), pursuant to which the Company is authorized to repurchase up to $2 million of its outstanding common shares. The timing and amount of repurchases under the program are determined by the Company’s management based on its evaluation of market conditions and other factors. This program has not set termination date and may be suspended or discontinued by at any time.

 

For the three and nine months ended September 30, 2026, no common shares were repurchased pursuant to the 2026 Share Repurchase Program.

 

F-22
 

 

Reverse Stock Split for Common Shares

 

On March 4, 2026, the Board of Directors of the Company approved a reverse stock split (“2026 Reverse Stock Split”) of the Company’s issued and outstanding common shares at a 1-for-20 ratio. The 2026 Reverse Stock Split was effective on April 2, 2026. The Company’s authorized number of shares and par value per share of common shares were not affected by the 2026 Reverse Stock Split. References made to share and per share information of common shares disclosed for all periods presented have been retroactively adjusted to reflect the effect of the 2026 Reverse Stock Split.

 

Shares Issued and Outstanding

 

As of September 30, 2026 and December 31, 2025, there were 1,515,328 and 1,270,991 shares of common shares issued and outstanding, respectively.

 

As of September 30, 2026 and December 31, 2025, there were 517 and 1,017 shares of preferred shares (designated as Series A convertible preferred shares) issued and outstanding, respectively.

 

NOTE 13 – NET INCOME (LOSS) PER SHARE

 

Basic net income (loss) per share is calculated on the basis of weighted average outstanding common shares. Diluted net income (loss) per share is calculated on the basis of basic weighted average outstanding common shares adjusted for the dilutive effect of stock options, RSUs and Series A convertible preferred shares. Potentially dilutive common shares are determined by applying the treasury stock method. Potentially dilutive common shares issuable upon conversion of the Series A convertible preferred shares are determined by applying the if-converted method.

 

The computation of basic and diluted net income (loss) per share for the three and nine months ended September 30, 2026 and 2025 is as follows:

 

   2026   2025   2026   2025 
   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2026   2025   2026   2025 
Numerator                    
Net income (loss) from continuing operations attributable to HeartCore Enterprises, Inc. common shareholders  $(583,872)  $45,611   $(3,210,859)  $(2,492,475)
Income (loss) from discontinued operations attributable to HeartCore Enterprises, Inc.  $(31,934)  $332,239   $(527,048)  $882,624 
Net income (loss) attributable to HeartCore Enterprises, Inc. common shareholders  $(615,806)  $377,850   $(3,737,907)  $(1,609,851)
Denominator                    
Weighted average number of common shares outstanding – basic and diluted   1,501,177    1,165,539    1,395,177    1,124,484 
                     
Net income (loss) from continuing operations attributable to HeartCore Enterprises, Inc. per common share – basic and diluted  $(0.39)  $0.04   $(2.30)  $(2.22)
Income (loss) from discontinued operations attributable to HeartCore Enterprises, Inc. per common share – basic and diluted  $(0.02)  $0.29   $(0.38)  $0.78 
Net income (loss) attributable to HeartCore Enterprises, Inc. per common share – basic and diluted  $(0.41)  $0.32   $(2.68)  $(1.43)

 

Potentially dilutive common shares are not included in the calculation of diluted net income (loss) per share if their effect would be anti-dilutive. The number of common shares that are not included in the calculation of diluted net income (loss) per share because to do so would have been anti-dilutive for the three and nine months ended September 30, 2026 and 2025 are as follows:

 

                 
   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2026   2025   2026   2025 
Anti-dilutive stock options and RSUs   55,665    70,960    56,054    71,618 
Anti-dilutive Series A convertible preferred shares   270,127    176,295    250,668    47,363 
Total anti-dilutive common shares   325,792    247,255    306,722    118,981 

 

F-23
 

 

NOTE 14 – DISCONTINUED OPERATIONS

 

HeartCore Japan

 

On July 24, 2025, in light of the intense competition of the software market in Japan, the Board of Directors of the Company approved to enter into a non-binding letter of intent to sell 100% of the outstanding shares of HeartCore Japan. The Company does not expect to have any continuing involvement in HeartCore Japan subsequent to the closing. The Company determines the sale of HeartCore Japan met the criteria for classification as held for sale. Additionally, the Company determines the sale of HeartCore Japan represents a strategic shift that has a major impact on its operations and financial results. Accordingly, all results of operations of HeartCore Japan have been removed from continuing operations and presented as discontinued operations in the unaudited consolidated statements of operations and comprehensive income (loss) for all periods presented. On October 31, 2025, the sale transaction was closed. The Company entered into a purchase agreement to sell 100% of the outstanding shares of HeartCore Japan to Smith Japan Holdings KK for a cash consideration of approximately $12 million, subject to price adjustment. For the nine months ended September 30, 2026, the Company received proceeds from sale of discontinued operations for HeartCore Japan of $1,005,946.

 

The following table summarizes the results of operations from discontinued operations, net of income tax for HeartCore Japan in the unaudited consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2026 and 2025:

 

   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2025   2025 
Revenues  $2,456,011   $6,724,813 
Cost of revenues   1,164,610    3,246,188 
Gross profit   1,291,401    3,478,625 
Operating expenses:          
Selling expenses   192,768    625,653 
General and administrative expenses   289,105    1,046,507 
Research and development expenses   248,997    534,371 
Total operating expenses   730,870    2,206,531 
Income from discontinued operations   560,531    1,272,094 
Other expenses   (5,715)   (15,533)
Income from discontinued operations before income tax expense   554,816    1,256,561 
Income tax expense   66,519    68,080 
Income from discontinued operations, net of income tax  $488,297   $1,188,481 

 

Sigmaways and Its Wholly-owned Subsidiaries

 

On March 5, 2026, in light of the intense competition of the software market in the United States, the Board of Directors of the Company approved to sell 51% of the outstanding shares of Sigmaways and its wholly-owned subsidiaries. The Company does not expect to have any continuing involvement in Sigmaways and its wholly-owned subsidiaries subsequent to the closing. The Company determines the assets of Sigmaways and its wholly-owned subsidiaries met the criteria for classification as held for sale. Additionally, the Company determines the sale of Sigmaways and its wholly-owned subsidiaries represents a strategic shift that has a major impact on its operations and financial results. Accordingly, all results of operations of Sigmaways and its wholly-owned subsidiaries have been removed from continuing operations and presented as discontinued operations in the unaudited consolidated statements of operations and comprehensive income (loss) for all periods presented. All assets and liabilities of Sigmaways and its wholly-owned subsidiaries have been presented separately as assets and liabilities of discontinued operations in the consolidated balance sheet as of December 31, 2025. On June 22, 2026, the sale transaction was closed. The Company entered into a purchase agreement to sell 51% of the outstanding shares of Sigmaways and its wholly-owned subsidiaries to Semaphore Technologies, Inc. for a cash consideration of up to $650,000, consisting of (i) closing cash consideration of $1,000, and (ii) additional cash consideration of up to $649,000, upon achievement of certain financial performance milestones. The Company assesses the collection risk from time to time and determines the collection of additional cash consideration is not probable based on the current financial performance of Sigmaways and its wholly-owned subsidiaries. For the nine months ended September 30, 2026, the Company received gross proceeds from sale of discontinued operations for Sigmaways and its wholly-owned subsidiaries of $1,000, net of cash divested of $28,351.

 

F-24
 

 

The following table summarizes the loss on sale of discontinued operations for Sigmaways and its wholly-owned subsidiaries on June 22, 2026:

   June 22, 
   2026 
Consideration  $1,000 
Less: net assets (liabilities) of discontinued operations   (1,455,323)
Add: non-controlling interests   (1,798,448)
Add: cumulative translation adjustment reclassified into earnings due to disposal of discontinued operations   (81,371)
Loss on sale of discontinued operations  $(423,496)

 

The following table summarizes the results of operations from discontinued operations, net of income tax for Sigmaways and its wholly-owned subsidiaries in the unaudited consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2026 and 2025:

 

   2026   2025   2026   2025 
   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2026   2025   2026   2025 
Revenues  $-   $1,738,336   $1,537,119   $5,360,897 
Cost of revenues   -    1,355,927    1,254,009    4,097,240 
Gross profit   -    382,409    283,110    1,263,657 
Operating expenses:                    
Selling expenses   -    12,682    15,526    41,983 
General and administrative expenses   -    558,354    550,513    1,584,461 
Total operating expenses   -    571,036    566,039    1,626,444 
Loss from discontinued operations   -    (188,627)   (282,929)   (362,787)
Other expenses   -    (18,384)   (26,193)   (58,032)
Loss on sale of discontinued operations   -    -    (423,496)   - 
Loss from discontinued operations before income tax expense   -    (207,011)   (732,618)   (420,819)
Income tax expense (benefit)   -    46    (54,681)   5,978 
Loss from discontinued operations, net of income tax   -    (207,057)   (677,937)   (426,797)
Less: loss from discontinued operations attributable to non-controlling interests   -    (67,267)   (151,521)   (146,818)
Loss from discontinued operations attributable to HeartCore Enterprises, Inc.  $-   $(139,790)  $(526,416)  $(279,979)

 

The following table summarizes the assets and liabilities of discontinued operations and non-controlling interests for Sigmaways and its wholly-owned subsidiaries as of June 22, 2026 and December 31, 2025:

 

    June 22,    December 31, 
    2026    2025 
Assets of discontinued operations             
Cash and cash equivalents   $ 28,351    $81,136 
Accounts receivable     407,803     685,035 
Prepaid expenses     46,982     54,512 
Current portion of long-term note receivable     100,000     100,000 
Property and equipment, net     16,124     16,124 
Operating lease right-of-use assets     14,293     11,668 
Security deposits     1,645     1,645 
Total assets of discontinued operations   $ 615,198    $950,120 
              
Liabilities of discontinued operations             
Accounts payable and accrued expenses   $ 722,242    $847,459 
Accrued payroll and other employee costs     585,413     445,344 
Short-term debt – related party     69,000     75,000 
Current portion of long-term debts     51,697     50,598 
Factoring liability     139,159     135,982 
Operating lease liabilities, current     18,411     15,012 
Other current liabilities     56,633     59,191 
Long-term debts     427,966     448,376 
Total liabilities of discontinued operations   $ 2,070,521    $2,076,962 
              
Non-controlling interests   $ (1,798,448 )  $(1,633,871)

 

F-25
 

 

HeartCore Luvina

 

On July 31, 2026, in light of the intense competition of the software market in Vietnam, the Board of Directors of the Company approved to sell 51% of the outstanding shares of HeartCore Luvina. The Company does not expect to have any continuing involvement in HeartCore Luvina subsequent to the closing. The Company determines the assets of HeartCore Luvina met the criteria for classification as held for sale. Additionally, the Company determines the sale of HeartCore Luvina represents a strategic shift that has a major impact on its operations and financial results. Accordingly, all results of operations of HeartCore Luvina have been removed from continuing operations and presented as discontinued operations in the unaudited consolidated statements of operations and comprehensive income (loss) for all periods presented. All assets and liabilities of HeartCore Luvina have been presented separately as assets and liabilities of discontinued operations in the consolidated balance sheet as of December 31, 2025. On August 3, 2026, the Company entered into a purchase agreement to sell 51% of the outstanding shares of HeartCore Luvina to Luvina Software, the non-controlling shareholder of HeartCore Luvina, for a cash consideration of $182,131. On August 17, 2026, the sale transaction was closed. For the nine months ended September 30, 2026, the Company received gross proceeds from sale of discontinued operations for HeartCore Luvina of $182,131, net of cash divested of $335,063.

 

The following table summarizes the loss on sale of discontinued operations for HeartCore Luvina on August 17, 2026:

 

   August 17, 
   2026 
Consideration  $182,131 
Less: net assets of discontinued operations   356,965 
Add: non-controlling interests   175,390 
Add: cumulative translation adjustment reclassified into earnings due to disposal of discontinued operations   (13,380)
Loss on sale of discontinued operations  $(12,824)

 

The following table summarizes the results of operations from discontinued operations, net of income tax for HeartCore Luvina in the unaudited consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2026 and 2025:

 

   2026   2025   2026   2025 
   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2026   2025   2026   2025 
Revenues  $58,862   $9,008   $505,345   $25,383 
Cost of revenues   46,868    24,533    395,716    24,533 
Gross profit (loss)   11,994    (15,525)   109,629    850 
Operating expenses:                    
General and administrative expenses   2,192    9,324    23,570    46,568 
Total operating expenses   2,192    9,324    23,570    46,568 
Income (loss) from discontinued operations   9,802    (24,849)   86,059    (45,718)
Other income (expenses)   826    (5,761)   1,289    10,507 
Loss on sale of discontinued operations   (12,824)   -    (12,824)   - 
Income (loss) from discontinued operations before income tax expense   (2,196)   (30,610)   74,524    (35,211)
Income tax expense   25,572    1,288    40,916    15,531 
Income (loss) from discontinued operations, net of income tax   (27,768)   (31,898)   33,608    (50,742)
Less: income (loss) from discontinued operations attributable to non-controlling interests   4,166    (15,630)   34,240    (24,864)
Income (loss) from discontinued operations attributable to HeartCore Enterprises, Inc.  $(31,934)  $(16,268)  $(632)  $(25,878)

 

The following table summarizes the assets and liabilities of discontinued operations and non-controlling interests for HeartCore Luvina as of August 17, 2026 and December 31, 2025:

 

    August 17,    December 31, 
    2026    2025 
Assets of discontinued operations             
Cash and cash equivalents   $ 335,063    $373,859 
Accounts receivable     58,693     22,830 
Prepaid expenses     1,450     323 
Other current assets     23,885     19,978 
Property and equipment, net     1,418     - 
Operating lease right-of-use assets     4,747     795 
Security deposits     2,965     2,971 
Other non-current assets     1,353     549 
Total assets of discontinued operations   $ 429,574    $421,305 
              
Liabilities of discontinued operations             
Accounts payable and accrued expenses   $ 5,945    $23,630 
Accounts payable and accrued expenses – related party     31,502     124,618 
Accrued payroll and other employee costs     14,409     23,130 
Operating lease liabilities, current     3,150     795 
Income tax payables     17,416     27,158 
Other current liabilities     187     5,377 
Total liabilities of discontinued operations   $ 72,609    $204,708 
              
Non-controlling interests   $ 175,390    $136,599 

 

F-26
 

 

Assets and liabilities classified as held for sale are reported at the lower of carrying amount or fair value less cost to sell. There was no valuation allowance against the assets classified as held for sale. As of the closing dates of the sales of Sigmaways and its wholly-owned subsidiaries and HeartCore Luvina, the assets and liabilities classified as held for sale and non-controlling interests were derecognized and loss on sale of discontinued operations was recorded.

 

The following table provides a reconciliation of cash and cash equivalents reported within the unaudited consolidated balance sheets that sum to the total of such amounts shown in the unaudited consolidated statements of cash flows:

 

   September 30,   December 31, 
   2026   2025 
Cash and cash equivalents – unaudited consolidated balance sheets  $976,594   $1,530,967 
Cash and cash equivalents – discontinued operations for Sigmaways and its wholly-owned subsidiaries   -    81,136 
Cash and cash equivalents – discontinued operations for HeartCore Luvina   -    373,859 
Cash and cash equivalents – unaudited consolidated statements of cash flows  $976,594   $1,985,962 

 

NOTE 15 – SEGMENT REPORTING

 

Operating segments are defined as components of an entity for which discrete financial information is available and is regularly reviewed by the CODM, the CEO of the Company, in making decisions regarding resource allocation and performance assessment. The Company determines its operations constitute a single operating segment and reportable segment in accordance with ASC Topic 280. The CODM assesses financial performance and decides how to allocate resources based on consolidated net income (loss) from continuing operations. Segment assets are reported on the Company’s consolidated balance sheets.

 

The following table summarizes the selected financial information with respect to the Company’s single operating segment and reportable segment for the three and nine months ended September 30, 2026 and 2025:

 

   2026   2025   2026   2025 
   For the Three Months
Ended September 30,
   For the Nine Months
Ended September 30,
 
   2026   2025   2026   2025 
Revenues  $162,409   $1,242,985   $269,852   $1,666,519 
Less:                    
Cost of revenues   146,354    141,460    529,562    331,962 
Selling expenses   34,818    82,036    104,021    296,632 
General and administrative expenses   1,119,034    817,160    2,986,544    2,488,822 
Operating income (loss) from continuing operations   (1,137,797)   202,329    (3,350,275)   (1,450,897)
Total other income (expenses)   544,854    (98,457)   (564,558)   (951,368)
Income (loss) from continuing operations before income tax expense (benefit)   (592,943)   103,872    (3,914,833)   (2,402,265)
Income tax expense (benefit)   (24,277)   2,039    (766,504)   33,377 
Net income (loss) from continuing operations  $(568,666)  $101,833   $(3,148,329)  $(2,435,642)

 

As of September 30, 2026 and December 31, 2025 and for the three and nine months ended September 30, 2026 and 2025, all long-lived assets and revenues generated are attributed to the Company’s operation in Japan.

 

NOTE 16 – SUBSEQUENT EVENTS

 

On October 6, 2026, the Company granted 37,980 RSUs pursuant to the 2023 Plan to three executives of the Company. The RSUs are fully vested on the grant date. The fair value of the RSUs at grant date is $66,655.

 

F-27
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), provide a safe harbor for forward-looking statements made by us or on our behalf. We and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission (“SEC”) and in our reports and presentations to stockholders or potential stockholders. In some cases, forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties can be found in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as the same may be updated from time to time, including in Part II, Item 1A, “Risk Factors,” of this Quarterly Report on Form 10-Q.

 

Although we believe the expectations reflected in our forward-looking statements are based upon reasonable assumptions, it is not possible to foresee or identify all factors that could have a material effect on the future financial performance of the Company. The forward-looking statements in this Quarterly Report on Form 10-Q are made on the basis of management’s assumptions and analyses, as of the time the statements are made, in light of their experience and perception of historical conditions, expected future developments and other factors believed to be appropriate under the circumstances.

 

Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q and the information incorporated by reference in this Quarterly Report on Form 10-Q to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

 

Unless the context otherwise requires, references herein to “we,” “us” or the “Company” refer to HeartCore Enterprises, Inc. (“HeartCore USA”) and its subsidiaries, including HeartCore Financial, Inc. and its branch office in Japan, Higgs Field Co., Ltd. (“Higgs Field”), HeartCore Luvina Vietnam Company Limited (“HeartCore Luvina”), and Sigmaways, Inc. (“Sigmaways”) and its subsidiaries.

 

Business Overview

 

In 2022, HeartCore USA started the Go IPO business, which supports Japanese companies listing on The Nasdaq Stock Market (“Nasdaq”) and the New York Stock Exchange (“NYSE”) in the United States. As of September 30, 2026, we have entered into consulting agreements with 16 companies to assist them in their IPO process, whereby we are entitled to receive from each company a consulting fee that ranges from $380,000 to $900,000 and warrants or stock acquisition rights to purchase 1% to 4% of the fully-diluted share capital of such companies that is exercisable on certain dates at an exercise price of $0.01 or JPY1 per share.

 

Prior to November 2025, we were also a leading software development company based in Tokyo, Japan. We provided software through two business units. The first business unit, our CX division, included a customer experience management business (the “CXM Platform”). The second business unit, our DX division, was a digital transformation business which provided customers with robotics process automation, process mining and task mining to accelerate the digital transformation of enterprises. In 2025, we made the strategic decision to sell our software business assets in Japan and to concentrate our efforts on our Go IPO consulting business. On October 31, 2025, the Company entered into a Purchase Agreement (the “HeartCore Japan Agreement”) with Smith Japan Holdings KK (“Smith Japan”), pursuant to which the Company agreed to sell to Smith Japan, and Smith Japan agreed to purchase (the “HeartCore Japan Sale”), all of the outstanding equity interests of HeartCore Co., Ltd., a then-wholly owned subsidiary of the Company (“HeartCore Japan”). The HeartCore Japan Sale closed on October 31, 2025.

 

1
 

 

Go IPO Consulting Services

 

Since February 2022, we have been offering Go IPO consulting services, which include the following (collectively, the “Services”):

 

  ● Assisting with introductions to law firms, underwriters and auditing firms, in order that clients can make their selections, at their sole discretion;
  ● Assisting in the preparation of documentation for internal controls required for an initial public offering and simultaneous listing on the Nasdaq, the NYSE or the NYSE American;
  ● Providing support services to remove problematic accounting accounts upon listing support;
  ● Translation of requested documents into English;
  ● Attend and, if requested by the other party, lead, meetings of management and employees;
  ● Provide support services related to the Nasdaq, the NYSE or the NYSE American listing;
  ● Conversion of accounting data from Japanese standards to accounting principles generally accepted in the U.S. (“U.S. GAAP”);
  ● Assist in the preparation of S-1 or F-1 filings;
  ● Creation of English web page; and
  ● Preparing an investor presentation/deck and executive summary of the operations.

 

In providing the Go IPO Services, we do not provide investment advice regarding the value of securities, nor do we engage in the solicitation of investors or the negotiation of securities transactions. We do not provide accounting or legal advice, and we do not act as an investment advisor or broker-dealer.

 

Pursuant to the terms of the consulting agreements with our clients, the parties agree that we will not provide the following services, among others: negotiation of the sale of the issuers’ securities; participation in discussions between the issuers and potential investors; assisting in structuring any transactions involving the sale of the issuers’ securities; pre-screening of potential investors; due diligence activities; and providing advice relating to valuation of or financial advisability of any investments in the issuers. Additionally, we do not take part in the selection of, or negotiation of terms with, law firms, underwriters or audit firms. Such selection and negotiation is the sole responsibility of the client.

 

Pursuant to the terms of the consulting agreements with the issuers, the issuers agree to compensate us as follows in return for the provision of Go IPO Services during the initial term of the consulting agreements:

 

  ● A cash fee payable in installment payments; and
  ● Issuance by the issuer to us of warrants or stock acquisition rights to acquire a number of shares of capital stock of the issuer, to initially be equal to a designated percentage of the fully diluted share capital of the issuer, subject to adjustment as set forth in the warrants or stock acquisition rights.

 

Recent Developments

 

Share Repurchase Program

 

During the first quarter of 2026, the Company’s Board of Directors (the “Board”) authorized a share repurchase program, pursuant to which the Company may repurchase up to $2.0 million of its outstanding shares of common stock. The Board authorized the Company to purchase its common stock from time to time on a discretionary basis through open market purchases, privately negotiated transactions or other means, including trading plans intended to qualify under Rule 10b5-1 of the Exchange Act, in accordance with applicable federal securities laws and other applicable legal requirements. The Company expects to fund these repurchases through existing cash balances. Decisions regarding the amount and the timing of purchases under the program will be influenced by the Company’s cash on hand, cash flows from operations, general market conditions and other factors, and the program may be modified, suspended or discontinued at any time. The Company is not obligated to acquire any particular amount of its common stock. This program has no set termination date. As of September 30, 2026 and November 16, 2026, the Company has not repurchased any shares of its common stock pursuant to its share repurchase program.

 

2
 

 

Reverse Stock Split

 

As previously disclosed, on June 30, 2025, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation, as amended (the “Certificate of Incorporation”), to effectuate a reverse stock split of the Company’s outstanding shares of common stock, at a ratio of no less than 1-for-2 and no more than 1-for-30, with such ratio to be determined at the sole discretion of the Board. On March 4, 2026, the Board approved a 1-for-20 reverse stock split of Company’s issued and outstanding common stock (the “Reverse Split”). Subsequently, the Company filed a certificate of amendment (the “Certificate of Amendment”) to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effectuate the Reverse Split. The Certificate of Amendment was effective for state law purposes at 4:00 p.m. Eastern Time on April 2, 2026 (the “Effective Time”), after the close of trading on the Nasdaq Capital Market (“Nasdaq”), such that the Company’s common stock began trading on Nasdaq at market open on April 6, 2026, on a post-Reverse Split basis.

 

As of the Effective Time, issued and outstanding shares of the Company’s common stock were automatically reclassified such that each 20 shares of pre-Reverse Split common stock became one share of common stock, with any fractional shares of common stock resulting being rounded up to the nearest whole share of common stock. The authorized number of shares, and par value per share, of the Company’s common stock were not affected by the Reverse Split.

 

Compliance with Nasdaq Minimum Bid Price Requirement

 

As previously disclosed, on May 6, 2025, the Company received written notice (the “Bid Price Notice”) from the Nasdaq Staff indicating that the Company was not in compliance with the Minimum Bid Price Requirement. The notification of noncompliance had no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. The Bid Price Notice indicated that the Company was provided 180 calendar days, or until November 3, 2025, in which to regain compliance. On November 4, 2025, the Nasdaq Staff notified the Company of its determination that the Company was eligible for an additional 180-day period, or until May 1, 2026, to regain compliance with the Minimum Bid Price Requirement.

 

On April 20, 2026, the Company received written notice from the Nasdaq Staff that the Company has regained compliance with the Minimum Bid Price Requirement and the matter has now been closed. Accordingly, the Company’s common stock continues to be listed and traded on the Nasdaq Capital Market.

 

Sale of 51% Interest in Sigmaways and Its Subsidiaries

 

On June 22, 2026, the Company entered into a Stock and Debt Purchase Agreement (the “Sigmaways Agreement”) with Semaphore Technologies, Inc. (“Semaphore”). Pursuant to the terms of the Sigmaways Agreement, the Company sold its entire 51% majority ownership interest in Sigmaways and its subsidiaries, consisting of 229,500 shares of capital stock (the “Sigmaways Shares”).

 

3
 

 

The purchase price for the Sigmaways Shares was up to $650,000, which reflects the uncertain and disputed nature of the value and collectability of the underlying assets. Pursuant to the terms of the Sigmaways Agreement, the payments are as follows:

 

  ● A cash payment of $1,000 at closing; and
  ● An earn-out amount of up to $649,000, payable within 10 days of the end of the 12-month period following closing, calculated as 10% of Sigmaways’ Gross Revenue (as defined in the Sigmaways Agreement) that exceeds $5,500,000.

 

The closing of the transactions contemplated by the Sigmaways Agreement occurred on June 22, 2026. Following the closing, the Company has no further operational involvement or obligations with respect to Sigmaways.

 

The Sigmaways Agreement contains customary representations, warranties, and covenants, including a maximum liability cap equal to the amount actually paid to the Company (except in cases of fraud).

 

Sale of 51% Interest in HeartCore Luvina

 

On August 3, 2026, the Company entered into a Capital Contribution Portion Transfer Agreement (the “Transfer Agreement”) with Luvina Software Joint Stock Company (“Luvina Software”), our non-controlling shareholder of HeartCore Luvina. Pursuant to the terms of the Transfer Agreement, the Company agreed to sell its entire 51% ownership interest in HeartCore Luvina, together with all rights and obligations attaching thereto and accrued up to the date of the Transfer Agreement, to Luvina Software in exchange for JPY29,000,000 (approximately $180,000).

 

The transactions contemplated by the Transfer Agreement closed on August 17, 2026.

 

The Transfer Agreement contains customary representations, warranties, and covenants.

 

Financial Overview

 

For the three months ended September 30, 2026 and 2025, we generated revenues of $162,409 and $1,242,985, respectively, and reported a net loss from continuing operations of $568,666 and a net income from continuing operations $101,833, respectively.

 

For the nine months ended September 30, 2026 and 2025, we generated revenues of $269,852 and $1,666,519, respectively, and reported a net loss from continuing operations of $3,148,329 and $2,435,642, respectively, and had net cash flows used in operating activities of continuing operations of $3,348,933 and $2,342,190, respectively. As noted in our unaudited consolidated financial statements, as of September 30, 2026, we had an accumulated deficit of $16,640,902.

 

Results of Operations

 

Comparison of Results of Operations for the Three Months Ended September 30, 2026 and 2025

 

The following table summarizes our operating results as reflected in our unaudited consolidated statements of operations and comprehensive income (loss) for the three months ended September 30, 2026 and 2025, respectively, and provides information regarding the dollar and percentage increase (or decrease) during such periods.

 

   For the Three Months Ended September 30, 
   2026   2025   Variance 
       % of       % of         
   Amount   Revenues   Amount   Revenues   Amount   % 
Revenues  $162,409    100.0%  $1,242,985    100.0%  $(1,080,576)   -86.9%
Cost of revenues   146,354    90.1%   141,460    11.4%   4,894    3.5%
Gross profit   16,055    9.9%   1,101,525    88.6%   (1,085,470)   -98.5%
                               
Operating expenses:                              
Selling expenses   34,818    21.4%   82,036    6.6%   (47,218)   -57.6%
General and administrative expenses   1,119,034    689.0%   817,160    65.7%   301,874    36.9%
Total operating expenses   1,153,852    710.4%   899,196    72.3%   254,656    28.3%
                               
Income (loss) from continuing operations   (1,137,797)   -700.5%   202,329    16.3%   (1,340,126)   -662.3%
                               
Other income (expenses)   544,854    335.5%   (98,457)   -7.9%   643,311    653.4%
                               
Income (loss) from continuing operations before income tax expense (benefit)   (592,943)   -365.0%   103,872    8.4%   (696,815)   -670.8%
                               
Income tax expense (benefit)   (24,277)   -14.9%   2,039    0.2%   26,316   1,290.6%
                               
Net income (loss) from continuing operations   (568,666)   -350.1%   101,833    8.2%   (670,499)   -658.4%
                               
Income (loss) from discontinued operations, net of income tax   (27,768)   -17.1%   249,342    20.1%   (277,110)   -111.1%
                               
Net income (loss)   (596,434)   -367.2%   351,175    28.3%   (947,609)   -269.8%
                               
Less: income (loss) from discontinued operations attributable to non-controlling interests   4,166    2.6%   (82,897)   -6.7%   87,063    105.0%
                               
Net income (loss) attributable to HeartCore Enterprises, Inc.   (600,600)   -369.8%   434,072    35.0%   (1,034,672)   -238.4%
                               
Dividends accrued on Series A convertible preferred shares   (15,206)   -9.4%   (56,222)   -4.6%   (41,016)   -73.0%
                               
Net income (loss) attributable to HeartCore Enterprises, Inc. common shareholders  $(615,806)   -379.2%  $377,850    30.4%  $(993,656)   -263.0%

 

4
 

 

Revenues

 

Our revenues decreased by $1,080,576, or 86.9%, to $162,409 for the three months ended September 30, 2026 from $1,242,985 for the three months ended September 30, 2025, primarily due to extension of IPO timeline by the Go IPO customers and fewer non-cash consideration recognized from successful IPO customer during the current period.

 

Cost of Revenues

 

Our cost of revenues remained relatively stable, which slightly increased by $4,894, or 3.5%, to $146,354 for the three months ended September 30, 2026 from $141,460 for the three months ended September 30, 2025.

 

Gross Profit

 

Our gross profit decreased by $1,085,470, or 98.5%, to $16,055 for the three months ended September 30, 2026 from $1,101,525 for the three months ended September 30, 2025, mainly driven by the decrease of revenue due to extension of IPO timeline by the Go IPO customers and fewer non-cash consideration recognized from successful IPO customer during the current period, while our cost of revenues remained relatively stable.

 

For the reasons discussed above, our overall gross profit percentage decreased by 78.7% to 9.9% for the three months ended September 30, 2026 from 88.6% for the three months ended September 30, 2025.

 

Selling Expenses

 

Our selling expenses decreased by $47,218, or 57.6%, to $34,818 for the three months ended September 30, 2026 from $82,036 for the three months ended September 30, 2025, primarily attributable to decrease in advertising and referral expenses, as we reduced certain marketing and referral activities and cancelled promotion campaigns with lower advertising performance during the current period.

 

General and Administrative Expenses

 

Our general and administrative expenses increased by $301,874, or 36.9%, to $1,119,034 for the three months ended September 30, 2026 from $817,160 for the three months ended September 30, 2025, primarily attributable to (i) an increase of $133,563 in salaries and welfare, due to the Company established new subsidiary, Higgs Field, in October 2025; (ii) an increase of $98,221 in consulting and professional fees related to our business restructuring, which the Company intended to seek new business opportunities in the direction of employee and human resource referral and financial services; and (iii) an increase of $65,536 in rental expenses mainly due to our relocation to an office with higher rental fees during the current period.

 

Other Income (Expenses), Net

 

Our other income (expenses) includes changes in fair value of investments in marketable securities, changes in fair value of investment in warrants, changes in fair value of derivative liability, interest income generated from bank deposits, interest expenses for insurance premium financing, other income, and other expenses. Total other income, net increased by $643,311, or 653.4%, to $544,854, total other income, net for the three months ended September 30, 2026, from total other expenses, net of $98,457 for the three months ended September 30, 2025, primarily attributable to (i) an increase of $421,585 in gain on fair value changes of investments in marketable securities due to fair value measurement across periods; (ii) an increase of $155,911 in change in fair value of investment in warrants due to fair value measurement across periods; and (iii) an increase of $119,726 in other income, net, which mainly contributed by foreign currency exchange gain for proceeds receivable from the sale of the discontinued operations.

 

5
 

 

Income Tax Expense (Benefit)

 

Income tax benefit was $24,277 for the three months ended September 30, 2026, representing an increase of $26,316, or 1,290.6%, from income tax expense of $2,039 for the three months ended September 30, 2025, mainly due to the Company recognized deferred income tax benefits due to reversal of deferred tax liabilities related to the gain recognized on the sale of discontinued operations of HeartCore Japan in connection with the collection of installment proceeds for sale of discontinued operations of HeartCore Japan during the period.

 

Income (Loss) from Discontinued Operations, Net of Income Tax

 

On October 31, 2025, the Company entered into the HeartCore Japan Agreement with Smith Japan in relation to the sale of 100% equity interest in HeartCore Japan. The sale of HeartCore Japan closed on October 31, 2025.

 

On June 22, 2026, the Company entered into the Sigmaways Agreement with Semaphore in relation to the sale of 51% equity interest in Sigmaways and its subsidiaries. The sale of Sigmaways and its subsidiaries closed on June 22, 2026.

 

On August 3, 2026, the Company entered into a Capital Contribution Portion Transfer Agreement (the “Transfer Agreement”) with Luvina Software Joint Stock Company (“Luvina Software”), our non-controlling shareholder of HeartCore Luvina. Pursuant to the terms of the Transfer Agreement, the Company agreed to sell its entire 51% ownership interest in HeartCore Luvina, together with all rights and obligations attaching thereto and accrued up to the date of the Transfer Agreement, to Luvina Software in exchange for JPY29,000,000 (approximately $180,000). The transactions contemplated by the Transfer Agreement closed on August 17, 2026.

 

The results of operations of HeartCore Japan, Sigmaways and its subsidiaries, and HeartCore Luvina are reported as discontinued operations for all periods presented, as the sale of HeartCore Japan, Sigmaways and its subsidiaries, and HeartCore Luvina represented a strategic shift that had a major impact on the Company’s operations and financial results. We reported a loss from discontinued operations, net of income tax, of $27,768 and an income from discontinued operations, net of income tax, of $249,342 for the three months ended September 30, 2026 and 2025, respectively.

 

Income (Loss) from Discontinued Operations Attributable to Non-controlling Interests

 

As mentioned above, we owned a 51% equity interest of Sigmaways and its subsidiaries before disposal on June 22, 2026, and 51% equity interest of HeartCore Luvina before disposal on August 17, 2026. Accordingly, we recorded income of $4,166 from discontinued operations attributable to non-controlling interests and loss of $82,897 from discontinued operations attributable to non-controlling interests for the three months ended September 30, 2026 and 2025, respectively.

 

6
 

 

Dividends Accrued on Series A Convertible Preferred Shares

 

On June 30, 2025, we issued 2,000 shares of Series A convertible preferred shares, which were granted a cumulative dividend of 10% per annum. Accordingly, we recorded dividends accrued on Series A convertible preferred shares of $15,206 and $56,222 for the three months ended September 30, 2026 and 2025, respectively.

 

Net Income (Loss) Attributable to HeartCore Enterprises, Inc. Common Shareholders

 

As a result of the foregoing, we reported a net loss attributable to HeartCore Enterprises, Inc. common shareholders of $615,806 for the three months ended September 30, 2026, representing a $993,656, or 263.0%, decrease from a net income attributable to HeartCore Enterprises, Inc. common shareholders of $377,850 for the three months ended September 30, 2025.

 

Comparison of Results of Operations for the Nine Months Ended September 30, 2026 and 2025

 

The following table summarizes our operating results as reflected in our unaudited consolidated statements of operations and comprehensive income (loss) for the nine months ended September 30, 2026 and 2025, respectively, and provides information regarding the dollar and percentage increase (or decrease) during such periods.

 

   For the Nine Months Ended September 30, 
   2026   2025   Variance 
       % of       % of         
   Amount   Revenues   Amount   Revenues   Amount   % 
Revenues  $269,852    100.0%  $1,666,519    100.0%  $(1,396,667)   -83.8%
Cost of revenues   529,562    196.2%   331,962    19.9%   197,600    59.5%
Gross profit (loss)   (259,710)   -96.2%   1,334,557    80.1%   (1,594,267)   -119.5%
                               
Operating expenses:                              
Selling expenses   104,021    38.5%   296,632    17.8%   (192,611)   -64.9%
General and administrative expenses   2,986,544    1,106.8%   2,488,822    149.3%   497,722    20.0%
Total operating expenses   3,090,565    1,145.3%   2,785,454    167.1%   305,111    11.0%
                               
Loss from continuing operations   (3,350,275)   -1,241.5%   (1,450,897)   -87.0%   1,899,378    130.9%
                               
Other expenses   (564,558)   -209.2%   (951,368)   -57.1%   (386,810)   -40.7%
                               
Loss from continuing operations before income tax expense (benefit)   (3,914,833)   -1,450.7%   (2,402,265)   -144.1%   1,512,568    63.0%
                               
Income tax expense (benefit)   (766,504)   -284.0%   33,377    2.0%   799,881    2,396.5%
                               
Net loss from continuing operations   (3,148,329)   -1,166.7%   (2,435,642)   -146.1%   712,687    29.3%
                               
Income (loss) from discontinued operations, net of income tax   (644,329)   -238.8%   710,942    42.7%   (1,355,271)   -190.6%
                               
Net loss   (3,792,658)   -1,405.5%   (1,724,700)   -103.4%   2,067,958    119.9%
                               
Less: loss from discontinued operations attributable to non-controlling interests   (117,281)   -43.5%   (171,682)   -10.3%   (54,401)   -31.7%
                               
Net loss attributable to HeartCore Enterprises, Inc.   (3,675,377)   -1,362.0%   (1,553,018)   -93.1%   2,122,359    136.7%
                               
Dividends accrued on Series A convertible preferred shares   (62,530)   -23.2%   (56,833)   -3.4%   5,697    10.0%
                               
Net loss attributable to HeartCore Enterprises, Inc. common shareholders  $(3,737,907)   -1,385.2%  $(1,609,851)   -96.5%  $2,128,056    132.2%

 

7
 

 

Revenues

 

Our revenues decreased by $1,396,667, or 83.8%, to $269,852 for the nine months ended September 30, 2026 from $1,666,519 for the nine months ended September 30, 2025, primarily due to extension of IPO timeline by the Go IPO customers and fewer non-cash consideration recognized from successful IPO customer during the current period.

 

Cost of Revenues

 

Our cost of revenues increased by $197,600, or 59.5%, to $529,562 for the nine months ended September 30, 2026 from $331,962 for the nine months ended September 30, 2025, as we spent more efforts and resources and incurred more outsourcing fees for Go IPO consulting services to enhance our Go IPO consulting customers experience with us.

 

Gross Profit (Loss)

 

Our gross profit (loss) decreased by $1,594,267, or 119.5%, to gross loss of $259,710 for the nine months ended September 30, 2026 from gross profit of $1,334,557 for the nine months ended September 30, 2025, mainly driven by the decrease of revenue due to extension of IPO timeline by the Go IPO customers and fewer non-cash consideration recognized from successful IPO customer during the current period, while our cost of revenues increased as we as spent more efforts and resources and incurred more outsourcing fees for Go IPO consulting services to enhance our Go IPO consulting customers experience with us.

 

For the reasons discussed above, our overall gross profit (loss) margin decreased by 176.3% to -96.2% for the nine months ended September 30, 2026 from 80.1% for the nine months ended September 30, 2025.

 

Selling Expenses

 

Our selling expenses decreased by $192,611, or 64.9%, to $104,021 for the nine months ended September 30, 2026 from $296,632 for the nine months ended September 30, 2025, primarily attributable to decrease in advertising and referral expenses, as we reduced certain marketing and referral activities and cancelled promotion campaigns with lower advertising performance.

 

8
 

 

General and Administrative Expenses

 

Our general and administrative expenses increased by $497,722, or 20.0%, to $2,986,544 for the nine months ended September 30, 2026 from $2,488,822 for the nine months ended September 30, 2025, primarily attributable to (i) an increase of $245,802 in salaries and welfare, due to the Company established new subsidiary, Higgs Field, in October 2025; (ii) an increase of $163,041 in rental, primarily due to our relocation to an office with higher rental costs during the current period; (iii) an increase of $179,770 in consulting and professional fees related to our business restructuring, which the Company intended to seek new business opportunities in the direction of employee and human resource referral and financial services; offset by (iv) a decrease of $73,413 in other miscellaneous operating expense as we implemented expense saving policy to cut down various operating expenses in order to save operating cash flows during the current period.

 

Other Expenses, Net

 

Our other income (expenses) includes changes in fair value of investments in marketable securities, changes in fair value of investment in warrants, changes in fair value of derivative liability, interest income generated from bank deposits, interest expenses for insurance premium financing, other income, and other expenses. Other expenses, net decreased by $386,810, or 40.7%, to $564,558 for the nine months ended September 30, 2026, from $951,368 for the nine months ended September 30, 2025, primarily attributable to a decrease of $533,049 in loss on fair value changes of investments in marketable securities due to fair value measurement across periods; (ii) an increase of $140,424 in other income, net, which mainly contributed by foreign currency exchange gain for proceeds receivable from the sale of the discontinued operations during the period; partially offset by an increase of $361,645 in other expenses, which mainly contributed by foreign currency exchange loss for proceeds receivable from the sale of the discontinued operations during the period.

 

Income Tax Expense (Benefit)

 

Income tax benefit was $766,504 for the nine months ended September 30, 2026, representing an increase of $799,881, or 2,396.5%, from income tax expense of $33,377 for the nine months ended September 30, 2025, mainly due to the Company recognized deferred income tax benefits due to reversal of deferred tax liabilities related to the gain recognized on the sale of discontinued operations of HeartCore Japan in connection with the collection of installment proceeds for sale of discontinued operations of HeartCore Japan during the period.

 

Income (Loss) from Discontinued Operations, Net of Income Tax

 

On October 31, 2025, the Company entered into the HeartCore Japan Agreement with Smith Japan in relation to the sale of 100% equity interest in HeartCore Japan. The sale of HeartCore Japan sale closed on October 31, 2025.

 

On June 22, 2026, the Company entered into the Sigmaways Agreement with Semaphore in relation to the sale of 51% equity interest in Sigmaways and its subsidiaries. The Sigmaways and its subsidiaries sale closed on June 22, 2026.

 

On August 3, 2026, the Company entered into a Capital Contribution Portion Transfer Agreement (the “Transfer Agreement”) with Luvina Software Joint Stock Company (“Luvina Software”), our non-controlling shareholder of HeartCore Luvina. Pursuant to the terms of the Transfer Agreement, the Company agreed to sell its entire 51% ownership interest in HeartCore Luvina, together with all rights and obligations attaching thereto and accrued up to the date of the Transfer Agreement, to Luvina Software in exchange for JPY29,000,000 (approximately $180,000). The transactions contemplated by the Transfer Agreement closed on August 17, 2026.

 

9
 

 

The results of operations of HeartCore Japan, Sigmaways and its subsidiaries, and HeartCore Luvina are reported as discontinued operations for all periods presented, as the sale of HeartCore Japan, Sigmaways and its subsidiaries, and HeartCore Luvina represented a strategic shift that had a major impact on the Company’s operations and financial results. We reported a loss from discontinued operations, net of income tax, of $644,329 and an income from discontinued operations, net of income tax, of $710,942 for the nine months ended September 30, 2026 and 2025, respectively.

 

Loss from Discontinued Operations Attributable to Non-controlling Interests

 

As mentioned above, we owned a 51% equity interest of Sigmaways and its subsidiaries before disposal on June 22, 2026, and 51% equity interest of HeartCore Luvina before disposal on August 17, 2026. Accordingly, we recorded loss from discontinued operations attributable to non-controlling interests of $117,281 and $171,682 for the nine months ended September 30, 2026 and 2025, respectively.

 

Dividends Accrued on Series A Convertible Preferred Shares

 

On June 30, 2025, we issued 2,000 shares of Series A convertible preferred shares, which were granted a cumulative dividend of 10% per annum. Accordingly, we recorded dividends accrued on Series A convertible preferred shares of $62,530 and $56,833 for the nine months ended September 30, 2026 and 2025, respectively.

 

Net Loss Attributable to HeartCore Enterprises, Inc. Common Shareholders

 

As a result of the foregoing, we reported a net loss attributable to HeartCore Enterprises, Inc. common shareholders of $3,737,907 for the nine months ended September 30, 2026, representing a $2,128,056, or 132.2%, increase from a net loss attributable to HeartCore Enterprises, Inc. common shareholders of $1,609,851 for the nine months ended September 30, 2025.

 

Liquidity and Capital Resources

 

As of September 30, 2026, we had $976,594 in cash and cash equivalents, as compared to $1,530,967 as of December 31, 2025. We also had $32,853 in accounts receivable as of September 30, 2026.

 

As of September 30, 2026, our working capital was $1,482,524. In assessing our liquidity, management monitors and assesses our cash and cash equivalents, our ability to generate sufficient revenues in the future, and our operating and capital expenditure commitments. We assess whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.

 

We incurred net loss from continuing operations for the three and nine months ended September 30, 2026 and incurred net cash flows used in operating activities of continuing operations for the nine months ended September 30, 2026, primarily due to the macroeconomic downturn environment. We also had accumulated deficit as of September 30, 2026.

 

The Company’s plan is to continue exploring strategic alternatives for raising additional funding for future operations through a combination of obtaining equity financing, entering into debt or other financing arrangements, and restructuring of operations to grow revenues and decrease expenses to supplement the Company’s liquidity. The Company’s ability to raise capital may be constrained by the price of and demand for the Company’s equity shares. Additional funding may not be available on favorable terms or at all, and could further dilute the Company’s current shareholders. Management cannot conclude as of the date of this report that its plans are probable of being successfully implemented. There can be no assurance that the Company will be able to obtain sufficient additional liquidity when needed or under acceptable terms, if at all.

 

The following table sets forth a summary of our cash flows for the periods indicated:

 

   For the Nine Months
Ended September 30,
 
   2026   2025 
Net cash flows used in operating activities of continuing operations  $(3,348,933)  $(2,342,190)
Net cash flows provided by investing activities of continuing operations   2,640,582    1,071,732 
Net cash flows provided by (used in) financing activities of continuing operations   (87,694)   1,935,392 
Net cash flows used in discontinued operations   (143,064)   (787,864)
Effect of exchange rate changes   (70,259)   26,577 
Net change in cash and cash equivalents   (1,009,368)   (96,353)
Cash and cash equivalents, beginning of the period   1,985,962    2,121,089 
Cash and cash equivalents, end of the period  $976,594   $2,024,736 

 

Cash Flows from Operating Activities of Continuing Operations

 

Net cash flows used in operating activities of continuing operations was $3,348,933 for the nine months ended September 30, 2026, primarily consisting of the following:

 

  ●

Net loss from continuing operations of $3,148,329;

  ●

Deferred income tax benefit of $796,046 mainly due to reversal of deferred tax liabilities.

  ● Offset by loss of $375,367 on fair value changes in investments in marketable securities due to fair value measurement;
  ● Offset by a non-cash lease expenses of $195,691.

 

10
 

 

Net cash flows used in operating activities of continuing operations was $2,342,190 for the nine months ended September 30, 2025, primarily consisting of the following:

 

  ● Net loss from continuing operations of $2,435,642;
  ● Warrants received as noncash consideration of $837,913 as one of our IPO consulting customers completed the IPO during the current period;
  ● Offset by loss of $908,416 on fair value changes in investments in marketable securities due to fair value measurement.

 

Cash Flows from Investing Activities of Continuing Operations

 

Net cash flows provided by investing activities of continuing operations amounted to $2,640,582 for the nine months ended September 30, 2026, primarily consisting of proceeds of $2,076,782 from the sale of marketable securities and proceeds of $825,663 from sales of discontinued operations, net of cash divested.

 

Net cash flows provided by investing activities of continuing operations amounted to $1,071,732 for the nine months ended September 30, 2025, for proceeds from the sale of marketable securities.

 

Cash Flows from Financing Activities of Continuing Operations

 

Net cash flows used in financing activities of continuing operations amounted to $87,694 for the nine months ended September 30, 2026, for repayment of insurance premium financing.

 

Net cash flows provided by financing activities of continuing operations amounted to $1,935,392 for the nine months ended September 30, 2025, primarily consisting of proceeds of $1,800,000 from the issuance of Series A convertible preferred shares and common shares related to a securities purchase agreement, net of share issuance costs, proceeds of $117,000 from the exercise of stock options, and proceeds of $103,942 from collection of subscription receivable, offset by repayment of $103,303 for insurance premium financing.

 

Cash Flows from Discontinued Operations

 

Net cash flows used in discontinued operations amounted to $143,064 for the nine months ended September 30, 2026.

 

Net cash flows used in discontinued operations amounted to $787,864 for the nine months ended September 30, 2025.

 

Contractual Obligations

 

Lease Commitment

 

The Company has entered into operating leases for office space. As of September 30, 2026, the future maturity of lease liabilities was as follows:

 

Year Ending December 31,  Operating 
Leases
 
Remaining of 2026  $72,022 
2027   288,087 
Total lease payments   360,109 
Less: imputed interest   (3,575)
Total lease liabilities   356,534 
Less: current portion   (284,622)
Non-current lease liabilities  $71,912 

 

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements as of September 30, 2026.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited consolidated financial statements. These unaudited consolidated financial statements are prepared in accordance with U.S. GAAP, which requires us to make estimates and assumptions that affect the reported amounts of our assets and liabilities and revenues and expenses, to disclose contingent assets and liabilities on the date of the unaudited consolidated financial statements, and to disclose the reported amounts of revenues and expenses incurred during the financial reporting period. We continue to evaluate the estimates and assumptions that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from those estimates. We believe there are no critical accounting policies and estimates for the nine months ended September 30, 2026.  

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective, due to existence of a material weakness previously disclosed under Item 9A. “Controls and Procedures” in our Annual Report on Form 10-K for our fiscal year ended December 31, 2025, as filed with the SEC on March 31, 2026, as the same may be amended from time to time.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

11
 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we are involved in various claims and legal actions arising in the ordinary course of business. To the knowledge of our management, there are no legal proceedings currently pending against us which we believe would have a material effect on our business, financial position or results of operations and, to the best of our knowledge, there are no such legal proceedings contemplated or threatened.

 

ITEM 1A. RISK FACTORS

 

Following the strategic disposition of Sigmaways and its subsidiaries, our revenue has become concentrated among a smaller number of key customers. The loss of, or a material reduction in business from, any of these customers, or a failure to collect outstanding receivables, could have a material adverse effect on our business, financial condition, and results of operations.

 

On June 22, 2026, we completed the sale of our entire 51% majority interest in Sigmaways and its subsidiaries. Following this transaction, we no longer consolidate or derive revenue from Sigmaways and its subsidiaries’ operational activities.

 

Prior to the disposition, a significant portion of our consolidated revenue was derived through Sigmaways and its subsidiaries. Following the sale of Sigmaways and its subsidiaries, our revenue from continuing operations is now significantly more concentrated among a smaller group of customers. For the three and nine months ended September 30, 2026, a limited number of customers accounted for a substantial majority of our revenues and outstanding accounts receivable. If we fail to retain these key clients or if they reduce their commitments, our consolidated revenue will decline disproportionately. Our revenues and cash flows may experience heightened volatility, making financial performance less predictable from period to period.

 

Our accounts receivable is concentrated among a small number of customers. Any deterioration in the financial condition or liquidity of these key customers, or general macroeconomic weakness in our primary geographic markets, could increase our credit risk and result in significant delay, default, or non-payment of outstanding accounts receivable.

 

Furthermore, the consideration of the disposition of Sigmaways and its subsidiaries consists of $1,000 upfront cash consideration and an earn-out consideration of up to $649,000 contingent on post-closing gross revenue thresholds over 12 months. We cannot provide assurance that any earn-out consideration will be realized.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

There have been no defaults in any material payments during the covered period.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

(a) None.

 

(b) There have been no material changes to the procedures by which security holders may recommend nominees to our Board of Directors since we last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K.

 

(c) During the quarter ended September 30, 2026, no HeartCore USA director or officer adopted or terminated a contract, instruction or written plan for the purchase or sale of HeartCore USA securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and/or a non-Rule 10b5-1 trading arrangement.

 

ITEM 6. EXHIBITS

 

Exhibit
Number
  Description of Document
10.1   Capital Contribution Portion Transfer Agreement, dated August 3, 2026, by and between the registrant and Luvina Software Joint Stock Company (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on August 7, 2026).
31.1*   Rule 13a-14(a) Certification of Principal Executive Officer.
31.2*   Rule 13a-14(a) Certification of Principal Financial Officer.
32.1**   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Principal Executive Officer and Principal Financial Officer.
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.
** Furnished herewith.

 

12
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

  HEARTCORE ENTERPRISES, INC.
     
Dated: November 16, 2026 By: /s/ Sumitaka Yamamoto
    Sumitaka Yamamoto
    Chief Executive Officer and President (principal executive officer)
     
Dated: November 16, 2026 By: /s/ Qizhi Gao
    Qizhi Gao
    Chief Financial Officer (principal financial officer and principal accounting officer)

 

13

 

Keep reading